



Sino-American
Pharmaceutical
Professionals
Association

2026 SAPA Annual Conference

**Navigating Dynamic Landscape,
Shaping BioPharma Future - Advancing
Healthcare Innovation in a Transforming World**



Saturday
September 26, 2026



Hyatt Regency New Brunswick
2 Albany St., New Brunswick, NJ 08901



<https://sapaweb.org>

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Greeting Message from the SAPA President



Greeting Message from the SAPA President

It is my great honor and pleasure to welcome you to the 2026 SAPA Annual Conference! This year's theme, "Navigating Dynamic Landscape, Shaping BioPharma Future — Advancing Healthcare Innovation in a Transforming World," reflects both the pace of change around us and the tremendous opportunities ahead.

The biopharma industry is undergoing profound transformation. Scientific breakthroughs, novel therapeutic modalities, and emerging technologies are opening new possibilities for treating diseases, while AI and data-driven technologies are reshaping how medicines are discovered, developed, and delivered. These advances are creating unprecedented opportunities to improve human health, while also challenging us to think differently about how we innovate, collaborate, and translate scientific discoveries into meaningful outcomes for patients.

In this dynamic environment, SAPA continues to serve as a bridge connecting science, innovation, leadership, and our broader professional community. Over the past year, we have continued to advance our mission through scientific programs, investment forums, career development initiatives, networking opportunities, and community activities that connect professionals, foster collaboration, and inspire the next generation of leaders.

The strength of SAPA comes from you - our members, volunteers, sponsors, and partners. Your expertise, dedication, and generosity make SAPA a vibrant and trusted community where ideas are exchanged, partnerships are built, and opportunities flourish.

As we gather at this year's conference, I encourage you to engage deeply with our speakers and fellow participants, explore emerging ideas, and share your perspectives. Together, let us navigate this dynamic landscape, embrace new opportunities, and help shape the future of biopharma and healthcare.

The future is not simply something we navigate - it is something we have the opportunity to shape.

Thank you for your continued trust, energy, and support of SAPA. I look forward to an inspiring conference and another year of collaboration, innovation, and progress.

With warmest regards,

Wei Ding, PhD

SAPA President
2026 SAPA Annual Conference Chair
Senior Director, Bioinformatics, Data Science, and AI, AstraZeneca Rare Diseases

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Table of Contents

Greeting Message from the SAPA President	1
Conference Program At-A-Glance	3
Hyatt Regency Hotel Meeting Space Floor Plan	4
About SAPA	5
SAPA Events	9
Conference Program	12
SAPA Corporate Sponsors	22

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Conference Program At-A-Glance

Saturday, September 26, 2026


09:00 – 09:10 AM	Opening Remarks
09:10 – 09:35 AM	Keynote: Li Chen, PhD, Hua Medicine
09:35 – 10:00 AM	Keynote: Matteo di Tommaso, Bristol Myers Squibb
10:00 – 10:25 AM	Keynote: Caroline McGregor, Merck & Co.
10:25 – 10:50 AM	Keynote: David Glass, Regeneron
10:50 – 11:00 AM	Coffee Break
11:00 – 11:50 AM	IQ Fireside Chat - AI in Pharma
11:50 – 12:00 PM	SAPA Election Announcement and Closing Remarks
12:10 – 12:55 PM	Lunch Break
12:00 – 01:00 PM	Lunch & Learn: NJ Government Resources (Session H)
01:00 – 03:10 PM	Session A: Drug Discovery - Novel Therapies on the Horizon
03:20 – 05:30 PM	Session B: Meeting New Challenges in CMC Development
01:00 – 03:10 PM	Session C: AI in Pharma: From Pilot to Production
03:20 – 05:30 PM	Session D: Clinical Development and Regulatory Affairs in the AI Era: Accelerating Evidence Generation and Decision Making
01:00 – 03:10 PM	Session E: Navigating New Horizons: Strategic Alliances, Capital, BD and Compliance in a Dynamic BioPharma Landscape
03:20 – 05:30 PM	Session F: Career Development - Voices from Industry: Diverse Paths to Success in Pharma & Biotech
01:00 – 05:30 PM	Session G: AI Workshop - Mastering AI Agents for Work and Life
05:30 – 06:30 PM	Reception
06:30 – 09:00 PM	SAPA Annual Gala

2026 SAPA Annual Conference


Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Hyatt Regency Hotel Meeting Space Floor Plan


First Floor



Second Floor



Lower Level



2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



About SAPA

美中醫藥開發協會
Sino-American Pharmaceutical
Professionals Association

Introduction to SAPA

SAPA was founded in 1993 in the US as a non-profit organization and since then has grown rapidly and become one of the most active and well-recognized professional organizations in the US. SAPA is headquartered in the Greater New York area (NJ/NY/CT) with six US regional chapters (SAPA-NE in New England, SAPA-GP in Greater Philadelphia, SAPA-CT in Connecticut, SAPA-DC in Greater Washington DC area, SAPA-NC in Research Triangle region, and SAPA-MW in Midwest area). SAPA members are engaged in drug discovery, pre-clinical & clinical development, manufacturing, regulation, marketing, and distribution of pharmaceuticals and biotech therapeutic products.

To fulfill its missions, each year SAPA and its regional chapters organize and sponsor many events including annual conferences, scientific symposia, seminars, workshops, and social activities in the US. These events have been supported and sponsored by many organizations, including major pharmaceutical, biotech and CRO companies.

SAPA Locations

- SAPA Headquarters: New Jersey, USA
- SAPA-CT (Connecticut Chapter): Connecticut, USA
- SAPA-DC (Greater Washington DC Chapter): Greater Washington DC areas, USA
- SAPA-GP (Greater Philadelphia Chapter): Philadelphia and other Pennsylvania areas, USA
- SAPA-MW (Mid-West Chapter): Illinois and Indiana areas, USA
- SAPA-NC (North Carolina Chapter): Research Triangle and surrounding areas, USA
- SAPA-NE (New England Chapter): Boston and New England areas, USA

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

President Office

President: Wei Ding, PhD

President-Elect: Lily Li, PhD

Immediate-Past President: Jack Wu, PhD MBA

Vice Presidents and Chapter Presidents

Kejie Li, PhD; Sidi Chen, PhD; Chuanwen Lu, PhD; Fei Chu, PhD; Bin Xiao, PhD; Xinjun Zhang, PhD

Executive Council (EC) Members (2025 – 2026)

Jiaying Liu, PhD

Yongle Pang, PhD *

Yu Zhou, PhD

Xi Cheng, MS, MPH

Linghua Harris Zhang, PhD MBA

Zheng Chen, PhD

Yang Wang, PhD

Danni Zhang, MS

*Department Directors

Junchi Lu, PhD *

Brian Jiang, MS *

Aiguo Xu, PhD *

Jerry Li, PhD

Dexi Yang, PhD

Siyu Jiang, MPH

Wille Wu, PhD

Xiaowei Sun, PhD *

Yong Guo, PhD *

Jiangchao Chen

Haiying (David) Liu, PhD

Jessica Cao, PhD

Shuai Li, PhD

Stephen Xue, MS

Board of Directors (2026 – 2028)

Lingxi (Larry) Cai, MBA

Xiaodong Chen, PhD

Feng Liu, PhD

Xin Du, PhD

Xiaodong (Frank) Gan, PharmD

Jun-Yan Hong, PhD

Xin-Jun Zhang, Ph. D.

Changhui(Charles) Li, MS, MBA

Huo (Alex) Li, PhD

Min Li, PhD

Yongmei Li, PhD

Bin Shi, Ph. D.

Jian Liu, PhD

Wansheng Jerry Liu, PhD, JD

Xiaole Shen, PhD, Chair

Haichen Yang, Ph. D.

Chao Zheng, Ph. D.

Shifeng (Bill) Wei, PhD

Jack Wu, PhD, MBA

Wei Ding, PhD

Mingde Xia, PhD

Yan Yan, MD, PhD

Jing Yang, PhD

Peng Sun, JD, Ph.D.

Hancheng Zhang, PhD

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Advisory Committee Members (2025-2027)

Active AC Members

Laura Hong
Young Shen
Jin Wang
Dan Zhang

Bo Liang
Bin Shi
Yan Xia

Bingli Ma
Weiqin (Tony) Tong - Chair
Lihu Yang

Honorary AC Members

Huimin (Harry) Chen
Xiyong Fu
Jian Li
Mark Lin
Li Shi
Yusheng Wu
Zhongda Zhang

Li Chen
Daming Gou
Kechun (Ken) Li
Puchun Liu
Huayi Tong
Li Yan

Jasmine Cui
Junning Lee
Xiaoling Li
Xiucan Liu
Jingsong Wang
Guohua Zhang

Former SAPA Presidents

Xiucan Liu, PhD	1993-94	Jisong Cui, PhD	2009-10
Guohua Zhang, PhD	1994-95	Jianji Wang, PhD	2010-11
Jun-Yan Hong, PhD	1995-96	Baoguo Huang, PhD MBA	2011-12
Bill S. Wei, PhD	1996-97	Handan He, PhD	2012-13
Puchun Liu, PhD	1997-98	Jiwen Chen, PhD	2013-14
Junning Lee, PhD	1998-99	Ning Yan, PhD	2014-15
Lihu Yang, PhD	1999-00	Weiguo Dai, PhD	2015-16
Rick Z-X Xu, PhD	2000-01	Lei Tang, PhD	2016-17
Li Chen, PhD	2001-02	Jian Liu, PhD	2017-18
Jianzhong Guo, PhD	2002-03	Xiaole Shen, PhD	2018-19
Min Li, PhD	2003-04	Wansheng Jerry Liu, PhD JD	2019-20
John J. Hu, PhD	2004-05	John Sun, PhD MBA	2020-21
Yusheng Wu, PhD	2005-06	Xiaodong Chen, PhD	2021-22
Charles Ying Wang, PhD	2006-07	Yongmei Li, PhD	2022-23
Hancheng Zhang, PhD	2007-08	Jack Wu, PhD MBA	2023-24
Mingde Xia, PhD	2008-09	Wei Ding, PhD	2024-25

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

2026 AC Organizing Committee

Chair: Wei Ding

Co-Chairs: Jack Wu, Lily Li

Junchi Lu

Xi Cheng

Dexi Yang

Shuai Li

Blair Bu

Jianda Yuan

Sherry Song

Danni Zhang

Wen Shi

Jianming Kang

Zhiwei Yin

Jason Zhong

Haiying Liu

Yang Wang

Stephen Xue

Xiaowei Sun

Zhou Yu

Layla Wu

Fei Zhan

Eric Rong

Brian Jiang

Linghua Harris Zhang

Yong Guo

Alex Song

Wansheng Jery Liu

Huanyu Chen

Willie Wu

Shengjie Xu

Yongle Pang

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

SAPA Events

Chapter	Event	Date
SAPA-HQ	Monthly Career Talk 8@8	Monthly, 2026
SAPA-HQ	SAPA Data Science Community Webinars	Bi-monthly, 2026
SAPA-HQ	HIFnR & MINE Salon	Bi-monthly, 2026
SAPA-HQ	Investment Forum @ JPM Week	11-Jan-26
SAPA-HQ	2026 SAPA Lunar New Year Celebration / Women's Day Gala	8-Mar-26
SAPA-HQ	SAPA Science and Career Symposium	2-May-26
SAPA-HQ	Healthcare Investment Forum and Roadshow	12-Jun-26
SAPA-HQ	Research Talent Awards / summer coordination	July - August, 2026
SAPA-HQ	Summer Picnic	16-Aug-26
SAPA-HQ	2026 SAPA Annual Conference	26-Sep-26
SAPA-CT & SAPA-DC	MedLaw Forum Live: FDA Regulation and IP Protection of AI	21-Mar-26
SAPA-CT	Career Development Bootcamp	11-Apr-26
SAPA-CT	Summer BBQ	16-Jun-26
SAPA-CT	Sea Fishing, Sponsor Summit	19-Jul-26
SAPA-CT	AI Symposium in Biomedicine	18-Sep-26
SAPA-CT	Annual Conference	5-Dec-26
SAPA-DC	Career Development & Innovation (Co-host with USIA/GWEC, CAST-DC, CAUCC)	10-Jan-26
SAPA-DC	Volunteer Boot Camp	31-Jan-26
SAPA-DC	New Year Networking Reception	21-Feb-26
SAPA-DC	JPM Recaps and DC event Planning	7-Mar-26
SAPA-DC	Career Development Workshop	15-Apr-26
SAPA-DC	Public Speaking	3-May-26

Chapter	Event	Date
SAPA-DC	Sponsor Workshop	5-May-26
SAPA-DC	Management and Entrepreneurship Map	7-Jun-26
SAPA-DC	Scientific Symposium	13-Jun-26
SAPA-DC	Global innovation workshop	26-Jul-26
SAPA-DC	RISW workshop and reception	16-Sept-26
SAPA-DC	Annual Conference	October 16-18, 2026
SAPA-DC	Policy Impact Forum / Appreciation	Mid November, 2026
SAPA-DC	Year-End Celebration & Awards and Holiday Gathering	Mid December, 2026
SAPA-GP	BioVerse Webinar	Monthly, 2026
SAPA-GP	Lunar New Year Celebration	21-Feb-26
SAPA-GP	SAPA-GP 2025 Annual Conference	March 19-20, 2026
SAPA-GP	SAPA-GP 2025 @Philly Cell and Gene Therapy Conference	May 8-9, 2026
SAPA-GP	Picnic	9-Aug-26
SAPA-GP	@Philly AI in Biopharma Executive Summit	10-Oct-26
SAPA-MW	ASCO-China Summit, their AC	May 29 - June 2, 2026
SAPA-NC	BBQ Team-Building Activity	February, 2026
SAPA-NC	1st SAPA-NC Annual Conference	April, 2026
SAPA-NC	Lake Lure Team-Building Activity	Aug, 2026
SAPA-NC	Networking Event with Deep Intelligent Pharma (DIP)	25-Sept-26
SAPA-NC	Networking Event with AI Generative Mining (AIGM)	8-Oct-26
SAPA-NE	Career Development workshop	7-Mar-26
SAPA-NE	Cell and gene Therapy Symposium @ Novartis	April, 2026
SAPA-NE	28th Annual Conference	13-Jun-26
SAPA-NE	Summer Outting	16-Aug-26
SAPA-NE	Scientific Symposium at GSK	16-Oct-26
SAPA-NE	Scientific Workshop @ Lilly	November, 2026
SAPA-NE	RoadShow with A&P	7-Nov-26

Chapter	Event	Date
SAPA-HQ	Monthly Career Talk 8@8	Monthly, 2027
SAPA-HQ	SAPA Data Science Community Webinars	Bi-monthly, 2027
SAPA-HQ	Investment Forum @ JPM Week	January, 2027
SAPA-HQ	2027 SAPA Lunar New Year Celebration / Women's Day Gala	March, 2027
SAPA-HQ	SAPA Science and Career Symposium	May, 2027
SAPA-HQ	Healthcare Investment Forum and Roadshow	June, 2027
SAPA-HQ	Research Talent Awards / summer coordination	July - August, 2027
SAPA-HQ	2027 SAPA Annual Conference	September, 2027
SAPA-GP	Lunar New Year Celebration	February, 2027
SAPA-GP	25th SAPA-GP Annual Conference	March 12-13, 2027
SAPA-GP	SAPA-GP 2025 @Philly Cell and Gene Therapy Conference	June 11-12, 2027
SAPA-MW	ASCO-China Summit	May 29 - June 2, 2027
SAPA-NC	2nd SAPA-NC Annual Conference	April, 2027
SAPA-NE	Career Development workshop	7-Mar-27
SAPA-NE	Cell and gene Therapy Symposium @ Novartis	April, 2027
SAPA-NE	28th Annual Conference	13-Jun-27
SAPA-NE	Summer Outting	16-Aug-27
SAPA-NE	Scientific Symposium and RoadShow with A&P @ GSK	October, 2027
SAPA-NE	Scientific Workshop	November, 2027

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Conference Program

Saturday, September 26, 2026

Plenary Session:

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

9:00 – 12:00 PM
Regency Ballroom DEF

Session Chairs : Wei Ding, PhD; Lily Li, PhD; and Jack Wu, PhD

9:00 – 9:10 AM

Opening Remarks

Wei Ding, PhD

SAPA President

Senior Director, Head of Bioinformatics and Data Sciences, AstraZeneca

9:10 – 9:35 AM

Keynote: Glucose Homeostasis: from Concept to Disease Modifying Therapy

Li Chen, PhD

Founder & CEO, Hua Medicine

Glucose homeostasis is regulated through various processes that maintain the primary energy supply for neurological and immunological functions. Glucokinase plays a central role in glucose homeostasis and regulates glucose sensitivity in multiple hormone secretions. Genetic and epigenetic defects of glucokinase and its regulatory protein are associated with diabetes, dyslipidemia and possibly neurodegeneration disease. Doraglatin, a first in class glucokinase positive allosteric modulator or GK activator, is developed for the treatment of T2DM and demonstrates its disease modifying benefit in clinical studies. The discovery of Dorzaglatin will be presented.

9:35 – 10:00 AM

Keynote: Pharma R&D in AI Era

Matteo di Tommaso

SVP, AI & Digital Tech

Bristol Myers Squibb

Developing a new medicine is one of the hardest problems in science. It takes many years, costs billions, and still fails far more often than it

succeeds. It is also intensely data driven, and the volume of biological and clinical data exceeds what any team can work through on its own. This talk shares an AI journey in drug discovery and development. It looks at how the next generation of tools are reshaping R&D and changing the way scientists work with data, from finding and validating targets to designing better molecules and running smarter trials. Drawing on real examples from Bristol Myers Squibb, this conversation offers perspective on where AI is already helping, where it is not yet, and what it takes to scale responsibly, so that more medicines reach patients sooner.

10:00 – 10:25 AM

Keynote: AI is transforming how the industry executes CMC - from development to patient

Caroline McGregor, PhD

VP, Pharm Analysis & Digital Technologies
Merck & Co.

Our pharmaceutical pipeline has grown roughly threefold while diversifying from small molecules into biologics, ADCs and macrocyclic peptides, with an expanding range of drug products and devices. Traditional CMC execution — document-centric transfer, manual authoring and reactive supply planning — cannot scale to meet that complexity. The constraint is not the science, and not the technology; it is disconnected knowledge. Data remains fragmented across systems and functions, so every technology transfer becomes a translation, every submission a reconstruction, and every AI ambition dependent on manual rework.

This presentation sets out an end-to-end vision for digitally enabled CMC and the practical path to reach it. The foundation is a CMC digital thread built before AI is scaled: a common data language, trusted data governed at source, lifecycle traceability from molecule to control strategy, and shared cross-functional ownership — so that submissions become an output of the data rather than the repository of the knowledge. On that foundation, three connected capability areas are described. Technology transfer shifts from episodic document handoffs to governed data, guided execution and continuous evidence, carrying process understanding intact from lab to plant and making analytical methods portable by design. Regulatory authoring applies AI to data-heavy sections, with demonstrated results including thousands of hours saved, substantial effort reduction and greater than 99% reduction in transcription errors. Clinical supply moves from manual forecasting and reactive firefighting to one live supply curve, in which task-specific and domain agents propose options against trusted shared data while people retain approval and accountability. The aggregate prize is a step change in execution: cycle times roughly halved in technology transfer, CMC off the critical path to file, materially shorter supply planning cycles, and approximately 20% additional capacity without proportional headcount growth. Delivery is framed as a sequenced multi-year roadmap — standards and feasibility in the near term, scaled integration and enterprise-wide digital workflows in the mid term, and fully integrated, AI-driven CMC execution in the long term. Value compounds over years rather than quarters, and the closing argument is one of shared industry effort: commit to it, standardize before automating, and build the expertise together.

10:25 – 10:50 AM

Keynote: Gene expression and specific pathways perturbing skeletal muscle mass and function

David Glass, MD

VP, Research, Regeneron

Elected Member, National Academy of Sciences

Understanding how gene expression and specific pathways shape tissue aging, muscle mass, and metabolic health is central to developing interventions against age- and obesity-related decline. We present two complementary studies. First, to identify genes and pathways consistently regulated across the rodent lifespan, we generated a high-N, age-related gene-expression atlas spanning 28 tissues in male and female C57BL/6J mice and 32 tissues in male Sprague Dawley rats (>5,000 samples) across multiple ages. We classified genes and pathways by trajectory—changing early, at mid-age, late, or linearly across lifespan. Linear changes dominated many, though not all, tissues, and certain tissues were relatively spared. We examined shared and divergent features of aging across tissues, sexes, and species, yielding a resource for understanding the timing and tissue-, sex-, and species-specificity of age-related change. Second, because myostatin negatively regulates muscle size and is a therapeutic target for preserving muscle, including during GLP1R-agonist-induced weight loss, we quantified the effects of reduced myostatin function in humans. A meta-analysis of ~1.1 million individuals showed that carriers of rare function-disrupting MSTN variants had decreased adiposity and increased lean mass, grip strength, and creatinine. Deep-learning segmentation of Dixon whole-body MRI (UK Biobank; 62,308 individuals) confirmed enlargement across muscle groups, exceeding 10% in heterozygous loss-of-function-like carriers. Structural modeling suggested that stabilizing inactive myostatin conformations mimics partial loss-of-function. Together, these studies illuminate the molecular architecture of tissue aging and the therapeutic potential of myostatin blockade for muscle and metabolic health.

10:50 – 11:00 AM

Coffee Break

11:00 – 11:50 AM

IQ Fireside Chat - AI in Pharma

Moderator:

Maureen Cruz, PhD

Principal – Science, Regulation, and Policy

Faegre Drinker Biddle & Reath LLP

Panelists:

Ciby Abraham, PhD

Executive Director, CMC Regulatory Affairs

Merck & Co.

Ankur Kulshrestha, PhD

Senior Director, Device & Combination Products Development

Bristol Myers Squibb

Jens Sydor, PhD

Vice President, DMPK

GSK

Plenary session fireside chat: Representatives from the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) will discuss the role of AI in the pharmaceutical industry and how IQ enables collaboration to advance the capabilities of the member companies. Topics will include AI in discovery and preclinical development, product development, challenges to scaling AI in R&D, regulatory trends, agency engagement, success stories, and risks to avoid/mitigate.

11:50 – 12:00 PM

SAPA Election Announcement and Closing Remarks

Lily Li, PhD

SAPA President-Elect

Associate Professor, UHart

12:00 – 01:00 PM

Lunch Break

Lunch and Learn

Unlocking Resources for Business Growth

12:10 – 12:55 PM

Garden State Ballroom ABC

Moderator:

Eric Rong

CEO

Rysteril Biopharmaceuticals

Panelists:

Ciby Abraham, PhD

Executive Director, CMC Regulatory Affairs

Merck & Co.

Ankur Kulshrestha, PhD

Senior Director, Device & Combination Products Development

Bristol Myers Squibb

12:10 – 12:20 PM

Presentation: Office of Business Engagement

Sho Islam, Director, Office of Business Engagement, Middlesex County

12:20 – 12:55 PM

Fireside Chat:

Eric Rong, CEO, Rysteril Biopharmaceuticals

Sho Islam, Director, Office of Business Engagement, Middlesex County

Yongmei Li, Ph.D, CEO, Axela Biosciences Inc

AFTERNOON SESSIONS

Parallel Session A: Drug Discovery

Novel Therapies on the Horizon

01:00 – 03:10 PM

Regency Ballroom ABC

Session Chairs: Dexi Yang, PhD, Harris Zhang, PhD and Haiying Liu, PhD

1:00 – 1:05 PM

Opening Remarks

Dexi Yang, PhD
Director, QuantX Biosciences

1:05 – 1:35 PM

Application of AI and High-Throughput Proteomics for Molecular Glue Discovery

Prof. Jin Wang, PhD
Director, Baylor College of Medicine

The discovery of molecular glues represents a transformative paradigm in targeted protein degradation and modulation. However, rationally identifying and optimizing these ternary complex-inducing small molecules remains a significant bottleneck. This presentation details an integrated, target-agnostic discovery platform that synergizes state-of-the-art high-throughput proteomics with advanced artificial intelligence to streamline molecular glue development.

First, we will discuss the deployment of GlueMiner, our specialized platform designed to systematically mine and analyze high-throughput proteomic screening data, enabling the rapid identification and prioritization of novel molecular glue hits. To rationalize these empirically derived hits and guide lead optimization, we subsequently utilize Glueplex. This advanced computational workflow leverages AlphaFold 3-like folding algorithms to accurately predict the three-dimensional structures and interaction interfaces of the glue-induced ternary complexes.

Finally, we will demonstrate the practical efficacy of this end-to-end approach through a comprehensive case study on VAV1. By highlighting our work on VAV1, we will illustrate how the seamless integration of GlueMiner's proteomic hit discovery and Glueplex's AI-driven structural predictions can successfully accelerate the identification and elucidation of therapeutically relevant molecular glues.

1:35 – 2:05 PM

The Importance of Conformation in PROTAC Design

Song Yang, PhD
Senior Research Investigator,
Arvinas

Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules whose conformational behavior influences ternary-complex formation,

degradation activity, and pharmacokinetic properties. This presentation reviews recent structural, biophysical, and computational studies demonstrating how macrocyclization, linker design, stereochemistry, and other conformational constraints affect PROTAC function. Molecular chameleon-icity - the ability to adopt different conformations in polar and nonpolar environments - may help reconcile the competing requirements of solubility and membrane permeability. Conformation-dependent descriptors, including radius of gyration, three-dimensional polar surface area, and the Bifunctional Bioavailability index, provide useful measures of permeability and absorption. PROTAC conformational ensembles also inform ternary-complex modeling, molecular dynamics simulations, and emerging artificial-intelligence methods for predicting degradation. Collectively, these findings establish molecular conformation as a critical design parameter connecting PROTAC structure, biological activity, and developability.

2:05 – 2:35 PM

Reimagining What Is Druggable: From Molecular Glue Discovery to Clinical Medicines

Lan Huang, PhD

CEO & Co-founder, SEED Therapeutics

Targeted protein degradation and molecular glues are redefining the boundaries of drug discovery by enabling therapeutic intervention against proteins historically considered “undruggable.” Recent clinical and business successes, including those from Revolution Medicines, further validate the transformative potential of molecular glue pharmacology. SEED Therapeutics has developed RITE3™ platform, a differentiated, target-centric molecular glue discovery platform that leverages novel E3 ligases to systematically identify small molecules capable of inducing productive target–E3 interactions. The platform is designed to be versatile and scalable and has generated six programs utilizing five novel E3 ligases across multiple therapeutic areas.

Importantly, RITE3 has advanced from discovery into clinical translation. The platform enabled the de novo design of an RBM39 degrader that is now in clinical studies, providing an important validation of SEED’s target-centric approach. SEED is also advancing two orally available degraders against CNS targets, demonstrating the potential to extend targeted protein degradation into challenging tissues and disease areas. By combining target-centric drug discovery, novel E3 biology, and an integrated discovery-to-development engine, SEED aims to transform molecular glue discovery from serendipity into a systematic and scalable modality—ultimately expanding the druggable proteome and translating previously inaccessible disease biology into clinical medicines.

2:35 – 3:05 PM

Epigenetic regulation of T cell alloimmunity and tumor immunity

Yi Zhang, MD, PhD

Director member, Professor,
Center for Discovery and Innovation (CDI),
Hackensack Meridian Health

Durable anti-tumor immunity requires T cells that expand sufficiently, persist after infusion, and retain effector function within the tumor. These

properties fail in roughly half of patients who relapse after CD19 CAR-T therapy. They are also compromised by the pan-immunosuppression used to prevent GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this seminar, we will address a central question: what epigenetic program sustains the proliferative and memory capacity of antigen-driven T cells, and how prolonged tumor exposure dismantle it. Four findings will be discussed. First, single-cell profiling of patient-derived CAR-T cells identified a proliferative, telomere-maintenance-high cluster marked by EZH2, and EZH2 proved required for leukemia eradication. These findings are contrary to the prevailing rationale for EZH2 inhibitors as immunotherapy adjuvants, which was built on tumor-cell and host studies that never tested CAR-T cells directly. Second, high tumor burden and sustained CAR signaling destabilize EZH2 protein and function in vivo, defining a T cell-intrinsic route to tumor immune evasion. Third, EZH2 and Ca^{2+} signaling are reciprocally coupled. EZH2 directly represses ITPR2, and EZH2 loss drives Ca^{2+} hyperactivation that impairs alloreactive and CAR-T survival. ITPR2 blockade or calcineurin inhibition during manufacturing restores function and limits terminal exhaustion. Fourth, CDK9 inhibition sensitizes B-cell malignancies through CASP8/GSDME-dependent death, enhancing CAR-T efficacy and memory differentiation. Future work will exploit the EZH2- Ca^{2+} circuit during manufacturing to imprint durable T cell fitness, and combine tumor-intrinsic sensitization with T cell-intrinsic EZH2 preservation to enhance the efficacy of T cell immunotherapies.

3:05 – 3:10 PM

Closing Remarks

Harris Zhang, PhD

President/Chief Scientific Officer,
Axela Biosciences

AFTERNOON SESSIONS

Parallel Session B:

Meeting New Challenges in CMC Development

03:20 – 05:30 PM

Regency Ballroom ABC

Session Chairs: Shuai Li, Ph.D and Yong Guo, Ph.D, MBA

3:20 – 3:25 PM

Opening Remarks

Yong Guo, Ph.D, MBA

Professor of Pharmaceutical Science
College of Pharmacy and Health Sciences
Fairleigh Dickinson University

3:25 – 3:55 PM

CMC Regulatory Considerations for ADCs

Xiang Cao, PhD

Director, Regulatory Affairs CMC,
Daiichi Sankyo

Antibody-drug conjugates (ADCs) combine the target specificity and prolonged circulation of monoclonal antibodies with the potent cytotoxic activity of small-molecule payloads through the use of specialized chemical linkers. However, the integration of a complex biologic, a highly potent small-molecule drug, and a linker technology into a single product results in a uniquely complex modality that presents significant development, manufacturing, and regulatory challenges. This presentation will explore the evolving regulatory landscape for ADCs and highlight key considerations through selected case studies that illustrate the complexities of ADC regulation across the product lifecycle.

3:55 – 4:25 PM

Need for Speed: Accelerating Drug Product Development from mAbs to New Modalities

Dingjiang Liu, PhD

Executive Director
Drug Product Development and Technology
Regeneron Pharmaceuticals Inc.

4:25 – 4:55 PM

From Technical Expert to Adaptive CMC Leader

Zheng Chen, PhD

Director/CMC Team Lead
AstraZeneca

As pharmaceutical portfolios continue to expand across diverse modalities and encounter accelerated development timelines, CMC teams are operating in the increasingly complex environment. Effective CMC leadership

requires strong technical knowledge and the ability to adapt to diverse development and business needs. This presentation explores how CMC leaders can effectively combine scientific judgment, learning agility, strategic vision, and cross functional stakeholder management to navigate uncertainty. It also discusses how leaders with strong technical backgrounds can help shape the future by building organizational capabilities and critical partnerships to sustain quality, expertise, and patient access in a rapidly changing environment.

4:55 – 5:25 PM

Scaling Biomanufacturing to 20,000L: A Large-Scale Monoclonal Antibody Production Case with High Titer, High Yield and High Concentration Formulation

Lu Xu, MBA

Executive Director
Global Business Development and Marketing
Altruist Biologics

As monoclonal antibody (mAb) therapeutics continue to expand across oncology, immunology, and rare disease applications, manufacturers face increasing pressure to deliver large-scale commercial supply while maintaining robust process consistency, product quality, and cost efficiency. The transition from clinical-scale production to commercial manufacturing introduces significant technical and operational challenges, particularly in maintaining process performance and product comparability during scale-up. This presentation showcases Altruist Biologics' successful scale-up of a mAb manufacturing process to 20,000L, highlighting key upstream optimization strategies, downstream process considerations, and cost-of-goods (CoG) reduction approaches to ultimately provide a scalable framework for industrial biomanufacturing operations seeking to maintain product quality and achieve high-concentration formulations at commercial scale.

5:25 – 5:30 PM

Closing Remarks

Shuai Li, PhD

Principal Scientist
Drug Product Development and Technology
Regeneron Pharmaceuticals Inc.

AFTERNOON SESSIONS

Parallel Session C:

AI in Pharma: From Pilot to Production

01:00 – 03:00 PM

Regency Ballroom DEF

Session Chairs: Brian Jiang, Jason Zhong, Xi Cheng

Session Theme: AI is rapidly reshaping pharmaceutical R&D, but the real challenge is moving beyond promising pilots to reliable, scalable, and trusted solutions. This session brings together AI leaders from leading biopharmaceutical companies to share practical perspectives on applying AI across R&D, improving scientific decision-making, and building the governance and infrastructure needed for enterprise-scale deployment.

HIGHLIGHTS

- Real-world AI applications across pharmaceutical discovery and development
- How AI is improving R&D and scientific decision-making
- Practical lessons on trust, validation, governance, and responsible deployment
- What it takes to move AI from pilots to scalable enterprise solutions
- Perspectives from leading pharma AI practitioners on what is working today, and what comes next

1:00 – 1:05 PM

Welcome & Framing

Brian Jiang

Digital & AI Solution Lead, Pfizer

1:05 – 1:30 PM

Applying AI/ML Clinical Development Across Pharmaceutical R&D From Discovery to Clinical Development

Antong Chen, PhD

Executive Director,

Data Science & Scientific Informatics, Merck

Artificial Intelligence is rapidly reshaping pharmaceutical R&D, moving beyond predictive analytics to foundation models, generative AI, multimodal learning, and autonomous agentic systems. As the pace of innovation accelerates, realizing value requires more than adopting new technologies. It demands deep scientific understanding, scalable platforms, and close partnership with domain experts across the drug development lifecycle. This presentation introduces the capabilities of the Data Science and Scientific Informatics (DSSI) organization at Merck and highlights how we are enabling AI-driven transformation across Discovery, Development Sciences, Translational Medicine, and Clinical Research. We will showcase DSSI's end-to-end expertise spanning machine learning, generative AI, agentic AI, multimodal foundation models, decision science, MLOps through real-world examples. The talk will also discuss the critical technical and organizational capabilities required to develop and operationalize AI solutions at scale.

1:30 – 1:55 PM

AI for Better R&D Decisions From prediction to scientific decision support

Chao-Hui Huang, PhD

Director, AI/ML Applications, Pfizer

1:55 – 2:20 PM

Enterprise AI Governance in Pharma: One Program for Regulation, Risk, and the Agentic Era

Patience Bin, JD

Senior Director, Enterprise AI & Data Governance,
Bristol Myers Squibb

AI now runs across the pharmaceutical value chain, and legal exposure has grown with it: high-risk classification under the EU AI Act, a patchwork of U.S. state laws, China's AI and data rules, GxP validation for adaptive models, promotional review of AI-generated content, and employment law scrutiny of AI-driven hiring. Privacy, security, and IP risks follow sensitive data and proprietary compound information into model inputs and outputs. This session presents a practical enterprise AI governance framework built on five pillars: policy, governance, risk assessment, ongoing monitoring, and training. It walks through a three-step, risk-tiered assessment model that screens systems for scope, scores regulatory, privacy, and cyber risk, and applies proportionate controls. It closes with the three trends reshaping AI risk in 2026, open weight models, MCP connectors, and agentic AI, and how to cover them with new checkpoints rather than new programs.

2:20 – 2:45 PM

AI in Pharma: Building, Governing, and Scaling Secure Enterprise AI

Thiru Venkatachalam, PhD

Vice President & Senior Partner
Enterprise AI Transformation Leader
IBM Consulting, Americas

2:45 – 2:55 PM

Sponsor Talk: Enterprise AI: From Token Burn to Balance Sheet Value

Tianhao Wu, PhD

Founder & Chief Humanity Officer
OPAIDA, Inc

Most enterprise AI programs generate impressive demos and expensive token bills, but never reach the balance sheet. The gap isn't model quality — it's trust: high-stakes operations can't run on a single model's word. This talk shows how opAIda closes that gap by embedding on-site Forward Deployed Engineers, deploying locally inside your own environment, using AI coding to build directly on your systems, and running self-improving models that cross-check each other, business rules, and historical data before anything reaches a human — turning Straight-Through Processing into a compounding, audit-ready asset instead of a token-burning liability.

2:55 – 3:00 PM

Closing Remarks

Xi Cheng, MPH, MS

Senior Healthcare Data Scientist,
ThinkSnow Medical Technology Co., Ltd.

AFTERNOON SESSIONS

Parallel Session D:

Clinical Development and Regulatory Affairs in the AI Era: Accelerating Evidence Generation and Decision Making

03:20 – 05:30 PM

Regency Ballroom DEF

Session Chairs: Xiaowei Sun, PhD, Jianda Yuan, MD, PhD, and Huanyu Chen, MS

3:20 – 3:25 PM

Opening Remarks

Xiaowei Sun, PhD

Senior Scientist, Translational Medicine, Bristol Myers Squibb

3:25 – 3:45 PM

Artificial Intelligence in Oncology Drug Development: A Balanced, End-to-End Framework

Jianda Yuan, MD, PhD

Senior Medical Director
Merck & Co.

To overcome the protracted timelines and exorbitant costs of oncology drug development, an end-to-end framework integrating Artificial Intelligence (AI) across the R&D lifecycle is essential. In discovery, generative AI and tools like AlphaFold compress target-to-lead timelines from years to months. During early clinical development, multimodal AI integrates radiomics and clinical data for superior Overall Survival prediction, driving robust Go/No-Go decisions. In late-stage trials, AI-derived digital twins and biomarkers optimize design, potentially reducing timelines by years. Despite this immense promise, AI currently remains largely investigational. Transitioning AI into a trusted core component of drug development requires rigorous prospective validation, bias mitigation, and strict adherence to evolving FDA and EMA regulations through a pragmatic, evidence-driven approach.

3:45 – 4:05 PM

From Stethoscope to Terminal: A Physician's Journey from Using AI to Building Trustworthy Medical AI Workflows

LunHsiang Yuan, MD, PhD

Deputy Director, Urology Department
National Taiwan University Hospital

Artificial intelligence is becoming part of medical practice, yet its adoption varies across clinical settings and tasks. Drawing on my experience as a physician, my PhD research in biomedical engineering, and my work developing AI workflows, this talk examines how advances in language technology translate into practical healthcare applications. It considers both the opportunities these tools offer and the conditions needed to evaluate their usefulness in everyday clinical work.

The discussion follows the development of medical language applications from natural language processing (NLP) to large language models (LLMs), with particular attention to developments since 2023. Examples include extracting information from clinical notes, summarizing medical literature, drafting documentation, and supporting clinical reasoning. Published studies and practical development experiences provide a basis for discussing how performance depends on the task, the available information, and the interaction between clinicians and AI systems.

A central question is why improvements in model capability have not led to consistent adoption throughout healthcare. The talk examines barriers such as fragmented data, integration with existing systems, variable output quality, the effort required for clinical review, and unclear responsibility for errors. It also considers practical engineering principles discussed by Anthropic, including starting with simple workflows, defining clear tasks, evaluating outputs systematically, and adding autonomy when its benefits can be demonstrated. These principles inform the design of clinical prototypes.

For clinicians, researchers, healthcare institutions, and the biomedical industry, the discussion focuses on how to assess AI within the processes where it will be used. Relevant outcomes include accuracy, review burden, time saved, patient safety, and effects on clinical decisions. The talk proposes a practical approach to collaboration: identify a specific need, define acceptable performance, test the workflow with its intended users, and monitor its behavior after implementation. This approach connects technical development with clinical evaluation and ongoing learning across organizations.

4:05 – 4:25 PM

AI Flywheel in Clinical Development: From Expert Judgment to Measurable Progress

Yue Shentu, PhD

Associate Vice President
Merck & Co.

Clinical development is often described as AI's next frontier, but it lacks the abundant training data that propelled recent advances. Trial data are scarce, costly, and confidential. Progress therefore cannot depend on ever larger datasets.

Instead, we can formalize the judgment of statisticians and regulators in scoring rubrics and benchmarks. These tools allow us to evaluate and improve AI copilots for trial design and analysis without moving patient data outside institutional firewalls. The cycle is straightforward: assign a benchmark task, collect an AI response, obtain an expert score, refine the agent harness and skills, and raise the difficulty. It resembles the benchmark-driven development of coding copilots, adapted to a field without public training corpora. These benchmarks will also establish the baseline for new cycles of development after each frontier model release.

This talk will showcase ongoing community efforts to develop clinical trial design bench and demonstrate how structured expert judgment can support measurable, cumulative progress in AI copilots for clinical trial design and analysis.

4:25 – 4:35 PM

Coffee Break

4:35 – 4:55 PM

Accelerating Evidence Generation with AI Endpoints: Bridging the Gap Between Early Efficacy Signals and Overall Survival in Oncology Clinical Development

Felix Baldauf-Lenschen

Founder & CEO

Altis Labs

Background: Overall survival (OS) remains the gold-standard endpoint in oncology, yet drug developers must rely on imaging endpoints like Objective Response Rate (ORR) and Progression-Free Survival (PFS) to make high-stakes R&D decisions. However, discordance between these early endpoints and OS highlight the need for better surrogate endpoints. AI models trained on comprehensive, longitudinal real-world data to predict survival outcomes may have the potential to anticipate OS treatment effects beyond traditional imaging endpoints.

Methods: In a post hoc analysis, Imaging-based PROgnostication (IPRO) was evaluated as a novel outcome measure and potential surrogate endpoint for OS in MARIPOSA, a global Phase 3 trial testing amivantamab + lazertinib vs. osimertinib in first-line EGFR+ advanced non-small cell lung cancer. IPRO scores were generated automatically from each baseline and on-treatment CT scan to measure patient-level prognostic changes. IPRO Response Rate (IRR) was defined as $\geq 50\%$ improvement over baseline IPRO. IRR treatment effects (i.e. IRR on treatment vs. control) were compared at early landmarks to treatment effects observed using traditional imaging endpoints and OS.

Results: 774 of 858 participants (90.2%) had evaluable baseline and on-treatment IPRO scores. Higher IPRO scores were strongly associated with longer OS. Starting at week 16, IRR yielded statistically significant treatment effects favoring amivantamab + lazertinib (OR 1.33; 95% CI, 1.03–1.71), which remained significant throughout landmarks. ORR treatment effects (OR 1.15 [0.78–1.70]) failed to anticipate the significant OS benefit (HR 0.75 [0.61–0.92]) observed in MARIPOSA.

Conclusions: AI-derived imaging endpoints can accelerate evidence generation to predict true OS benefit. Had IPRO been prospectively implemented in MARIPOSA, a statistically significant treatment effect would have been detected 11 months prior to the primary PFS analysis and 26 months prior to the final OS analysis. AI endpoints may enable clinical trial sponsors to make more confident early R&D decisions, optimize trial efficiency, and accelerate the delivery of life-extending therapies to patients.

4:55 – 5:15 PM

Regulatory Strategy as a Development Accelerator: Building the Right Evidence at the Right Time

Melody Dai, PhD, RAC, PMP

Regulatory & Product Development Executive

Global Molecular Solutions LLC

Successful drug development requires more than generating sufficient evidence for approval. It requires generating the right evidence at the right

time to enable the next critical decision. When integrated early across nonclinical, CMC, clinical, and commercial planning, regulatory strategy can provide a framework for identifying critical uncertainties, defining evidence needs, and aligning development activities with health authority expectations. This presentation will explore how a lifecycle-oriented regulatory strategy can accelerate development by working backward from the intended product profile and registration objectives, while preserving flexibility as science, technology, and regulatory expectations evolve. It will examine how decisions made early in development, including those related to translational evidence, manufacturing strategy, patient population, dose, endpoints, and study design, can shape the path to approval, and how emerging technologies and data-driven approaches are expanding the ways evidence can be generated and interpreted. Ultimately, regulatory strategy can move beyond compliance to become an active driver of development decisions, risk reduction, and a more efficient path from scientific innovation to an approvable medicine.

5:15 – 5:30 PM

Closing Remarks

Jianda Yuan, MD, PhD
Senior Medical Director
Merck & Co.

AFTERNOON SESSIONS

Parallel Session E:

Navigating New Horizons: Strategic Alliances, Capital, BD and Compliance in a Dynamic BioPharma Landscape

01:00 – 03:10 PM

Garden State Ballroom ABC

Session Chairs: Jun (Stephen) Xue, MS, Wansheng Jerry Liu, Ph.D., J.D.

1:00 – 1:05 PM

Opening Remarks

Wansheng Jerry Liu, Ph.D., J.D.

Partner & Chair of China Practice
Fox Rothschild LLP, Princeton, New Jersey

Jun (Stephen) Xue, MS

General Manager
ThalassaX Therapeutics US

1:05 – 2:10 PM

Legal Panel: Safeguarding Your Business Transactions from Legal, Accounting, and Regulatory Perspectives

Mini talk #1: Preparing for a Venture Capital Investment

Vincent A. Vietti, JD

Office Managing Partner
(Princeton) & Co-Chair of Public
Companies Practice
Fox Rothschild LLP

This short presentation will introduce, at a high level, how entrepreneurs and emerging companies can effectively prepare for the due diligence process when seeking venture capital investment from institutional investors. Drawing from practical experience advising companies across the pharmaceutical, biotechnology, medical device, and technology sectors, the discussion will highlight typical information requests and key areas of focus for investors.

Mini talk #2: From Data to Security: CFIUS and the Data Security Program in 2026

Ran He, PhD, JD

Founding Partner
THC Lawyers/InnovaNexus Venture

This mini-talk will examine how U.S. national security regulation is increasingly extending beyond traditional foreign investment review to encompass access to sensitive U.S. data. Using CFIUS and the evolving U.S. Data Security Program as practical examples, the presentation will highlight key considerations for life sciences, technology, and cross-border companies when structuring investments, partnerships, and data-related transactions in 2026.

Mini talk #3: Decoding Biotech BD: Valuation of Intangible Assets and Cross-Border Tax Pitfalls in US-China Deals

Caroline Lu, MS, CFA

Principal

UHY LLP

Cross-border biotech business development (BD) deals between the US and China navigate complex valuation and tax hurdles. Valuing intangible assets requires accounting for clinical trial success rates, regulatory risks, and patent lifecycles within discounted cash flow (DCF) models, while cross-border tax management demands careful navigation of transfer pricing, capital gains taxes, withholding taxes, and strict regulatory oversight on R&D expenses and technology exports in both jurisdictions.

2:10 – 3:15 PM

Panel Discussion: Leading Through Volatility: Resilient BD and Investment Strategy for Pharma & Biotech

Carla Lema Tome, PhD, MBA

VP of Business Development, Otsuka Pharmaceutical US

John Wang, PhD, MBA

SVP & Chief Strategy Officer, Gan & Lee Pharmaceuticals

Dan Zhang, MD, MPH

CSO of Peking Union Innovation Hub, Co-Chairman & Co-founder of Hillgene Biopharma

Stanislav Glezer, MD

Managing Director, Outcome Capital

Le Zhan, Ph.D.

SVP & Chief Strategy Officer, Gan & Lee Pharmaceuticals

Blake Salisbury

SVP, Business Development, Innovent Biologics

AFTERNOON SESSIONS

Parallel Session F:

Career Development - Voices from Industry: Diverse Paths to Success in Pharma & Biotech

03:20 – 05:30 PM

Garden State Ballroom ABC

Session Chairs: Qi (Alex) Song, PhD, Blair Bu, BMgt, and Yang Wang, PhD

3:20 – 3:25 PM

Opening Remarks

Blair Bu, BMgt
Senior Partner,
Life Science & Healthcare,
IntelliPro

Qi (Alex) Song, PhD
Principal Scientist,
Predictive biology & AI,
BMS

3:25 – 4:05 PM

Panel Discussion: Global Capability as the New Career Moat: Thriving in an Era of Constant Change

Victor Sun, PhD
Executive Director, Research Platform,
Innovent Biologics

Amy Spinney, MBA
Global Director of Product Management,
Fresenius Medical Care

Lorena Kuri, MS
Inclusion and Community Impact Lead,
BMS

Zhen Ma, PhD
Director,
CMC management,
Wuxi Biologics

This panel examines how professionals can build a "career moat"—a unique, defensible set of skills—by cultivating global capabilities. We will discuss how to navigate cross-cultural market dynamics, bridging the gap between scientific expertise and commercial strategy, and maintaining resilience amidst constant industry change.

4:05 – 4:45 PM

AI Reshaping Pharma Careers: Which Roles Will Disappear, Which Will Thrive, and How Leaders Should Prepare

Yingchao "YZ" Zhang, PhD
Co-founder & Chief AI Officer,
OpAlda

Bingxin Shen, PhD

Director, AI Solution Delivery, Business Insights & Technology,
BMS

Lan Luo, PhD

Assoc. Prin. Scientist,
Biostatistics,
Merck

Yirui Chen, PhD

Scientist,
computational biology,
Biogen

Qi (Alex) Song, PhD

Principal Scientist,
predictive biology & AI,
BMS

AI is rapidly transforming every stage of the drug development in the pharmaceutical industry. Traditional roles are evolving, new functions are emerging, and leadership expectations are changing. This panel will explore which pharma jobs are most vulnerable to AI disruption and what new roles and skillsets are emerging; How biotech and pharma leaders should redesign organizations; How scientists and executives can future-proof their careers.

4:45 – 5:25 PM

Panel Discussion: Mock Interview

Lorena Kuri, MS

Inclusion and Community Impact Lead,
BMS

Amy Spinney, MBA

Global Director of Product Management,
Fresenius Medical Care

Yirui Chen, PhD

Scientist,
Computational Biology,
Biogen

Zhen Ma, PhD

Director,
CMC management,
Wuxi Biologics

This panel provides opportunities to interact with top industry leaders to get practical experience for job interview preparation. You will hear the feedback from experienced professionals, navigating your next career move towards successful job offers.

5:25 – 5:30 PM

Closing Remarks

Blair Bu, BMgt
Senior Partner,
Life Science & Healthcare,
IntelliPro

Qi (Alex) Song, PhD
Principal Scientist,
Predictive Biology & AI,
BMS

AFTERNOON SESSIONS

Parallel Session G:

AI Workshop - Mastering AI Agents for Work and Life

01:00 – 05:30 PM

Conference Room B/C

Session Theme: AI agents can carry your standards forward instead of starting from scratch every time. This session moves through three stages: orchestrating a personal chief-of-staff agent across your projects and team, teaching an agent your resume-tailoring judgment once as a live-demoed Skill, and building your own website and personal brand just by describing what you want. It closes with a hands-on Build & Pitch, Shark Tank style, with prizes on the line. AI amplifies who you already are. Direction is the real skill.

1:00 – 1:10 PM

Opening Remarks

Zhiwei Yin, PhD
Associate Director,
AI for Clinical Development (AICD),
Bristol Myers Squibb

1:10 – 2:10 PM

Orchestrate AI Across Work and Life

Zhiwei Yin, PhD
Associate Director,
AI for Clinical Development (AICD),
Bristol Myers Squibb

2:10 – 3:10 PM

Build a Resume-Polishing Skill in Real Time

Junchi Lu, PhD
Associate Director,
Global Supply Chain,
Bristol Myers Squibb

3:10 – 3:20 PM

Coffee Break

3:20 – 4:20 PM

Build Anything: Your Personal Website and Beyond

Ming Tommy Tang
Director, AstraZeneca

4:20 – 5:25 PM

Build & Pitch: Hands-on Session, Shark Tank Challenge & Prizes

Junchi Lu, PhD
Associate Director,
Global Supply Chain,
Bristol Myers Squibb

5:25 – 5:30 PM

Closing Remarks

Junchi Lu, PhD
Associate Director,
Global Supply Chain,
Bristol Myers Squibb

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Biographies of Speakers and Panelists



Ciby Abraham, PhD
Executive Director, CMC Regulatory Affairs
Merck & Co.

Ciby Abraham, Ph.D., is an Executive Director in CMC Regulatory Affairs at Merck. Prior to joining Merck, he served as Senior Director of CMC Regulatory Affairs at AstraZeneca. Earlier, he was a CMC Team Leader at the U.S. Food and Drug Administration (FDA). His diverse experience spans regulatory affairs, pharmaceutical formulation development, analytical method development, and manufacturing. He was also licensed by the New York State Board of Pharmacy to release compounded pharmaceutical products for commercial distribution.

Dr. Abraham earned a Ph.D. in Chemistry from Johns Hopkins University, an M.S. in Chemistry from St. John's University, and a B.S. in Chemistry from Binghamton University.



Felix Baldauf-Lenschen
Founder & CEO
Altis Labs

Felix Baldauf-Lenschen is the Founder and CEO of Altis Labs, the AI endpoint company accelerating clinical trials. Felix founded Altis on the premise that AI's greatest potential lies in generating better evidence, faster. In close partnership with leading cancer centers, his team trained IPRO, its prognostic AI model, on longitudinal imaging, clinical, and outcomes data spanning over 500,000 cancer patient years. When used as an outcome measure in Phase I-III oncology trials, IPRO detects treatment effects earlier and more reliably than conventional imaging endpoints, helping drug developers bring the most effective new treatments to patients sooner.



Patience Bin, JD
Head of AI and Data Governance,
Law and Compliance
Bristol Myers Squibb

Patience Bin leads enterprise AI and data governance at Bristol Myers Squibb, where she defines the global strategy for governing AI and data across the company. She builds and scales the

frameworks that enable responsible AI adoption and lawful data use, advises leadership across the full AI lifecycle on generative and high-risk systems, and represents the company on responsible AI before regulators, standards bodies, and industry forums.

Her governance practice is built on fifteen years as a global compliance lawyer. Before BMS, she stood up the first enterprise AI governance framework at another Fortune 500 pharmaceutical company while leading its global anti-corruption, conflicts, and human rights programs across more than 120 markets. She previously served as General Counsel and Chief Compliance Officer for Asia Pacific at a global Fortune 500 beauty company, leading Legal, Compliance, and Government Affairs across the region, and as Group Head of Anti-Corruption for a global consumer goods group. She began her career in white-collar defense at DLA Piper and Mayer Brown, representing multinationals in FCPA and cross-border investigations before the DOJ and SEC.

Patience brings a systems view to governance: reading a global business as a single interconnected whole, understanding both the technology and the regulatory and human context around it, and building frameworks that hold across all of it.



Xiang Cao, Ph.D
Director, Regulatory Affairs CMC
Daiichi Sankyo

Xiang Cao is currently the Director of Regulatory Affairs CMC, at Daiichi Sankyo, where he has contributed to the commercial submissions of three late-stage antibody-drug conjugate programs and two early-stage antibody programs. Prior to joining Daiichi Sankyo, he worked at Johnson & Johnson as an Analytical Scientific Integrator, leading analytical matrix teams supporting both early- and late-stage bispecific antibody programs. He began his industry career at Bristol Myers Squibb as an Analytical Scientist, where he supported analytical development across a range of biologics programs. Throughout his career, Xiang has developed broad expertise in CMC regulatory strategy and analytical development for biologics, with experience spanning early development through commercial submission.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Antong Chen, PhD
Executive Director
Head of Data Science and
Scientific Informatics
Merck & Co., Inc.

Antong Chen earned a B.S. in Information Engineering from Xi'an Jiaotong University (2003), an M.S. in Electrical Engineering from Rose-Hulman Institute of Technology (2005), and a Ph.D. in Electrical Engineering from Vanderbilt University (2012), specializing in medical image analysis. He joined Merck & Co., Inc. and Merck Research Lab IT (MRL IT) in 2012, focusing on data science, analytics, and AI for drug safety and efficacy. As Executive Director of Data Science and Scientific Informatics in MRL IT, he leads a global team developing solutions in image analysis, NLP, bioinformatics, representation learning, signal processing, decision science, and ML-Ops to support the R&D of the company.



Zheng Chen, Ph.D
Director/CMC Team Lead
AstraZeneca

Zheng Chen is a cross-functional CMC leader and project leader with 20 years of pharmaceutical development experience spanning biologics and small molecules. She currently serves as Director & CMC Team Lead at Alexion, AstraZeneca Rare Disease, within the Product Development and Clinical Supply Organization, where she provides strategic CMC leadership across development programs and leads cross-functional teams through complex development, regulatory, and lifecycle challenges.

Throughout her career, Zheng has contributed to, managed, and led the development of 30+ assets across diverse modalities and stages of development, from preclinical through post-marketing. She has held roles of increasing responsibility at major global pharmaceutical companies, including Bristol Myers Squibb/Celgene, Merck, and Eli Lilly, building broad expertise across CMC development, technical strategy, program leadership, and cross-functional execution.

At Alexion/AstraZeneca, Zheng has led multiple high-impact biologics programs and CMC initiatives, including leading a late-stage cross-functional team through BLA/MAA submission activities; developing country-specific CMC strategies; leading a lifecycle management team that successfully demonstrated 10X process scale-up capability; and directing an early-phase, non-platform asset team with CMC strategy and clinical trial design within scope. In her current leadership role, she brings together scientific, technical, regulatory, clinical, and operational perspectives to establish development strategies, align stakeholders, manage complex risks and trade-offs, and drive teams toward critical program milestones.



Yirui Chen, PhD
Scientist,
COMPUTATIONAL BIOLOGY,
Biogen

Yirui Chen, Ph.D., is a computational biologist at Biogen, where she applies bioinformatics, statistical modeling, and machine learning to support drug discovery and development. Her work focuses on analyzing multi-omics data, including bulk and single-cell RNA sequencing, proteomics, and alternative splicing, to understand disease biology, identify biomarkers, and evaluate therapeutic responses. Yirui earned her Ph.D. in mathematical modeling and brings interdisciplinary expertise spanning computational biology, genomics, data science, and artificial intelligence.



Maureen Cruz, PhD
Principal – Science, Regulation,
and Policy
Faegre Drinker Biddle & Reath
LLP

Maureen Cruz is currently a Principal at Faegre Drinker Biddle & Reath LLP. Maureen is a strategy consultant with close to 20 years of professional experience in project management, biomedical research, and scientific communication. Maureen works with leaders in the global pharmaceutical and biotechnology industries to advance science and address emerging regulatory and compliance challenges by providing technical, strategic, and project management services.

Maureen has worked with clients to establish and manage multi-stakeholder research collaborations, address regulatory compliance issues, engage with global health authorities, and convene in scientific workshop and conference settings. As the lead Science Advisor of the IQ Consortium Secretariat, she manages a multidisciplinary team that supports the IQ Consortium, a global organization that advances science and technology to develop transformational solutions that benefit patients, regulators, and the broader R&D community. Maureen has a PhD in Neuroscience from Georgetown University and an MPH from Columbia University.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Li Chen, PhD
Founder & CEO, Hua Medicine

Dr. Chen Li, founder, Executive Director, and Chief Executive Officer of Hua Medicine, founded and leads Hua Medicine to discover and develop clinically differentiated medicines in China for the global market. Under his leadership, Hua Medicine has successfully brought a diseasemodifying, first-in-class glucokinase activator (GKA), HuaTangning® (dorzagliatin tablets, HMS5552), into the China market. Dorzagliatin is approved by China's National Medical Products Administration (NMPA) for type 2 diabetes, with its unique mechanism of action restoring impaired glucose homeostasis. During this period, Hua Medicine raised US\$200 million from equity markets and achieved RMB 1.5 billion in strategic partnership milestone revenues. He also built an integrated R&D, manufacturing, and commercialization ecosystem through partnerships across academia, industry, healthcare, and business sectors. In 2026, HuaTangning® achieved year-over-year sales growth of more than 70%. Hua Medicine is an innovative drug development and commercialization company with its headquarters in Shanghai, China, and R&D and commercial operations in the United States and Hong Kong, China. The company focuses on developing novel therapies for patients with unmet medical needs worldwide, as well as breakthrough technologies and products that drive global innovation in diabetes care.

Dr. Chen received his B.S. degree in Chemistry from Zhengzhou University in 1982, his M.S. degree in Chemistry from East China Normal University in 1985, and his Ph.D. from Iowa State University in 1992. He joined Roche's U.S. Research Center in 1992, where he served in a variety of leadership positions, including Senior Research Scientist, Head of High-Throughput Technologies, and member of Roche's Global Chemistry Leadership Team. In 2004, Dr. Chen returned to China to establish Roche China R&D Center and served as its Founding Director and Chief Scientific Officer, responsible for formulating and implementing Roche's drug R&D strategy in China. In 2010, he founded Hua Medicine, leading the development of a glucokinase activator (GKA) for the treatment of type 2 diabetes. His achievements have been recognized with numerous national honors. He is an inventor of 202 granted patents, 383 patent applications and an author with about 70 publications in leading journals including Nature Medicine, The Lancet Diabetes & Endocrinology, Nature Communications, PNAS, Diabetes, Diabetes, Obesity and Metabolism, JACS, and JOC.



Melody Dai, PhD, RAC, PMP
Regulatory & Product Development
Executive
Global Molecular Solutions LLC

Dr. Melody Dai, PhD, RAC, PMP, is a Regulatory & Product Development Executive at Global Molecular Solutions LLC with more than 24 years of experience leading global regulatory strategy, CMC development, and product development across ophthalmology, advanced therapies, biologics, rare diseases, oncology, and hematology. She advises emerging biotechnology companies on regulatory strategy, FDA interactions, CMC, and integrated product development from early development through long-term registrational planning and commercialization readiness.

Previously, she held leadership positions including VP of Regulatory Affairs & Product Development at Novasenta, Executive Director of Regulatory Affairs at Adverum Biotechnologies, Director of Regulatory Affairs at AbbVie, Associate Director of Regulatory Affairs at Amicus Therapeutics, and Project Leader at Pfizer. Throughout her career, she has led global regulatory and CMC strategies for innovative therapies, supporting INDs, CTAs, and multiple marketing applications from early development through commercialization, including several successful FDA approvals.

Dr. Dai received her PhD in Biophysical Chemistry from Rutgers University, following a BS in Chemistry from Peking University and postdoctoral training at the University of Pennsylvania. She serves on the Scientific Committee of the American Society of Gene & Cell Therapy (ASGCT) and the Global Education Committee of the Healthcare Businesswomen's Association (HBA), and has served as an HBA mentor.



David Glass, MD
VP, Research, Regeneron
Elected Member, National Academy of Sciences

David J. Glass, MD, is a Vice President of Research at Regeneron Pharmaceuticals, overseeing a group focused on Aging and Age-associated Disorders. He's also the Director of Regeneron's Postdoctoral Fellowship program. Dr. Glass teaches courses on Experimental Design, and on the History and Philosophy of Experimentation in Biology; these courses are given via his Senior Lecturer position in the Department of Cell Biology at

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Harvard Medical School, and as an Adjunct Professor in the Department of Genetics & Development at Columbia University's Vagelos School of Medicine. He holds a BS from Columbia, an MD from New York Medical College and conducted postdoctoral work at Columbia University. He's an elected fellow of AAAS and ASCI, and an elected member of the National Academy of Sciences. He is the co-author of more than 140 peer-reviewed research articles on cell signaling mechanisms in neuromuscular junction formation, skeletal muscle atrophy & hypertrophy, obesity, and mechanisms associated with aging. He's the author of "Experimental Design for Biologists," published by Cold Spring Harbor Press, which is now in its 2nd edition.



Stanislav Glezer, MD
Managing Director
Outcome Capital

Stanislav Glezer, MD MBA is a Managing Director at Outcome Capital, strategic advisory firm and an investment bank, specialized in life sciences. Most recently, Dr. Glezer, was with Inogen Inc, a medical technology company, where he served as an Executive Vice President, R&D and Chief Medical Officer. Under his leadership, the company has secured an MDR certification, developed and obtained 510k clearance for a couple of innovative devices, acquired of a French medical technology company, and completed several clinical trials and Real World Evidence projects resulting in peer reviewed publications and posters at international conferences. Prior to joining Inogen, Dr. Glezer worked for Becton, Dickinson and Company, Adocia S.A. a biotechnology company, Novo Nordisk, Inc., Sanofi and other Pharma companies. Dr. Glezer holds a Doctor of Medicine with Honors from Moscow State University of Medicine and Dentistry and an MBA from California Coast University. He has completed training in Health Economics and Clinical Research at McGill University and the CEO Program at Columbia University Business School.



Chao-Hui Huang, PhD
Director, AI/ML Applications
Pfizer Inc.

Chao Hui Huang (Ph.D.) is Director, AI/ML Applications at Pfizer Oncology R&D in San Diego, where he plays a key role in applying artificial intelligence to cancer research and drug develop-

ment. His research interests center on spatial biology, histopathological/biomedical image analysis, and generative AI, with particular focus on the synergy between these three areas. With a PhD and over 25 years of experience in AI/ML and the biopharmaceutical industry, he has held research and leadership roles at Merck, A*STAR Singapore, and Pfizer. He founded Pfizer's Machine Learning Special Interest Group, a community that grew to more than 270 participants, and has led the development of several AI platforms used to analyze cancer tissue and accelerate research. He is the author of more than 40 scientific publications, including work published in the Nature portfolio of journals and IEEE venues, and has chaired and led workshops at AAAI and CVPR.



Ran He, PhD, JD
Founding Partner
THC Lawyers/InnovaNexus Venture

Dr. Ran He is a lawyer licensed in New York, California, and Canada, and the Founder of THC Lawyers, a fast-growing international law firm with offices in Manhattan, Silicon Valley, Toronto, and Vancouver. His practice focuses on technology law, capital markets and venture consulting, commercial litigation, and cross-border matters involving the United States, Canada, and China. He has represented global pharmaceutical companies, NASDAQ-listed corporations, Chinese state-owned and listed enterprises, and high-profile individuals in complex commercial and IP transactions, IPOs, dispute resolution, and global wealth protection and management. Dr. He also advises established companies and startups on innovation, technology commercialization, venture development, and capital markets. He founded InnovaNexus Consulting and InnovaNexus Venture, creating an integrated platform connecting law, technology, business strategy, and capital formation.

A frequent conference speaker and longtime law and business school instructor, Dr. He holds a Ph.D. in Biochemistry and Molecular Biology and completed postdoctoral training in drug development at Johns Hopkins School of Medicine before earning his J.D. He also serves in leadership roles with organizations including SAPA-CT, East CACS, and FACL.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Ankur Kulshrestha, PhD
Senior Director, Device & Combination Products Development
Bristol Myers Squibb

Ankur S Kulshrestha PhD is Senior Director, Drug Product Development & Head, Drug Device Combination Products at Bristol Myers Squibb. He leads device development efforts focused on selecting, designing and advancing development of medical device technology to enable effective delivery of medicines while elevating patient experience to ensure clinical & commercial success.

He has about 20 years of industry experience spanning across areas of material science, formulation development, End to End Sterile drug product development, drug delivery and combination drug product development. Ankur holds PhD in Materials Chemistry from NYU Tandon School of Engineering. Before joining BMS, he worked at Becton Dickinson Company and Johnson & Johnson where he led numerous product and technology development efforts.

He has strong external industry leadership presence. He served on the Editorial Board of the PDA Journal of Pharmaceutical Science and Technology, actively engaged in SC Consortia sustainability benchmarking initiative and chairs the PFAS Drug Product Working Group within IQ Consortium. He has authored more than 40 articles in international journals including co-authoring PDA Technical report, has number of issued patents and edited books entitled "Polymers for Biomedical Applications" and "Biomaterials". In 2003, he was awarded Presidential Green Chemistry Challenge Award from US EPA.



Lorena Kuri, MS
Inclusion and Community Impact Lead,
BMS

Lorena Kuri is a pharma executive with over 20 years of experience in commercial and clinical operations across global teams — always guided by an inclusive lens. Prior to joining Bristol Myers Squibb, she held multiple commercial roles at Novartis spanning country, regional, and global levels, building a broad and deep understanding of the pharmaceutical landscape across diverse markets and geographies. As an Inclusion &

Community Impact Lead at Bristol Myers Squibb, she provides strategic oversight for the Black Organization for Leadership and Development (BOLD), the Organization for Latino Achievement (OLA), and the Pan Asian Network (PAN), championing inclusion as both a business imperative and a catalyst for health equity. Throughout her career, Lorena has been a driving force in advancing Health Equity and Diversity in Clinical Trials at BMS, elevating underrepresented voices. Lorena holds a Master's in Human Capital from Universidad Anáhuac México Sur and a DEI Certificate from Cornell University. She is fluent in English, Spanish, and Portuguese. Beyond her work at BMS, Lorena is actively engaged with HISPA, Women of Color in Pharma, the Red Shoe Movement, the SGM Alliance, and her hometown's diversity committee.



Yongmei (Maggie) Li, Ph.D.
CEO, Axela Biosciences Inc.
SAPA President (2022-2023)
SAPA-CT President (2014-2015)

Dr. Yongmei (Maggie) Li is the CEO of Axela Biosciences, a company dedicated to translating breakthrough scientific discoveries into transformative therapies and medical devices. She previously served as CEO of EmerTher Company, focusing on the application of superparamagnetic bead technology in the biomedical field, and spent over a decade at Boehringer Ingelheim Pharmaceuticals as a Senior Principal Scientist in drug metabolism and pharmacokinetics. Dr. Li holds a Ph.D. from the University of Illinois College of Pharmacy, has authored 20+ scientific publications, contributed to two book chapters, and holds more than 10 patents. An active leader in the life sciences community, she also served as President of SAPA and SAPA-CT, promoting scientific excellence and cross-cultural collaboration.



Wansheng Jerry Liu, Ph.D., J.D.
Partner & Chair of China Practice
Fox Rothschild LLP,
SAPA President 2019-2020

Jerry Liu is a Partner and the firmwide Chair of China Practice Group of Fox Rothschild LLP, a 1000-lawyer U.S. law firm. He practices in wide areas of intellectual property and corporate laws, including patent and trademark prosecution, litigation and legal opinions, contract review, formation of business

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

entities, and business transaction, etc. He serves clients from individuals and start-up companies to Fortune 500 companies, including assisting a number of major Chinese pharmaceutical companies in IP protection and conducting business in the U.S., and has handled due diligence for U.S. big pharma or research institute's investment, M&A and licensing deals valued from multi-million to multi-billion dollars.

Prior to law practice, Jerry worked as a Senior Research Investigator in process development at Bristol-Myers Squibb Company. Besides SAPA President in 2019-2020 and Editor-in-Chief of Rutgers Law Record in law school, Jerry is serving as the Delegate of the New York Intellectual Property Law Association (NYIPLA) to the CNIPA/U.S. Bar Liaison Council and General Counsel of the USTC Alumni Association of Greater New York (USTCAAGNY). He is an honoree of 2022 Outstanding 50 Asian Americans in Business by the Asian American Business Development Center in New York and has been selected to the "IAM Patent 1000" list (2020-2026) and the list of ranked attorneys by Chambers USA for Intellectual Property (2025 & 2026).

Jerry obtained Ph.D. in Organic Chemistry with Professor Sir Derek H. R. Barton (Nobel Prize, 1969) from Texas A&M University, J.D. from Rutgers University School of Law, and B.S./M.S. in Chemistry/Polymer Science from University of Science and Technology of China (USTC). A frequent speaker on IP laws and FDA regulations, Jerry has over 20 scientific and legal publications and four U.S. patents.



Caroline Lu, MS, CFA
Principal
UHY LLP

Caroline Lu is a Principal at UHY LLP ("UHY") and a Chartered Financial Analyst (CFA), with extensive experience in financial reporting and strategic advisory services. Caroline plays a key role in advising companies on U.S. acquisitions and investments, providing critical guidance on due diligence, tax-efficient investment structures, and identifying strategic investment opportunities.

Prior to joining UHY, Caroline was part of the Strategy and Transactions practice at EY LLP. There, she specialized in valuation analyses supporting strategic planning, mergers and acquisitions, tax structuring, corporate restructuring, divestitures, and joint ventures.

Earlier in her career, Caroline was a member of the Mergers and Acquisitions group at Fresenius Medical Care. In this role, she delivered valuation consulting services for a variety of transactions, including acquisitions, divestitures, start-ups, and joint ventures.



Dingjiang Liu, Ph.D
Executive Director
Drug Product Development and
Technology
Regeneron Pharmaceuticals Inc.

Dingjiang (Dean) Liu, Ph.D. is currently Executive Director in Drug Product Development and Technology at Regeneron Pharmaceuticals Inc. (Tarrytown, NY). Dean's current work is focused on formulation and drug product development of protein therapeutics and genetic medicines, including monoclonal antibody, bispecific antibody, antibody drug conjugates, peptide, AAV, LNP and siRNA from research to commercialization. He has successfully led product development, commercialization, and life cycle management for 7 FDA approved products. In the past 20 years, Dean has accumulated extensive experience in developability assessment, drug product development and manufacturing strategy, shelf-life stability and compatibility and in-use stability of biological drug products and application of QbD in development of biologics. He has authored/co-authored more than 70 scientific papers and patents. Dean graduated from Fudan University (Shanghai, China) with a BS degree in Chemistry; then from University of Wisconsin-Milwaukee with a Ph.D in Chemistry and Biochemistry. Dean worked at Schering Plough (now Merck Co.) and Amgen prior to joining Regeneron.



Junchi Lu, PhD
Associate Director,
Global Supply Chain,
Bristol Myers Squibb

Junchi Lu is an Associate Director at Bristol Myers Squibb, where she architects AI and advanced analytics solutions across the Global Supply Chain — spanning network supply AI agents, predictive risk assessment, and clinical supply forecasting. As a hybrid professional at the intersection of data science, supply chain strategy, and patient impact, she specializes in solving the problems no single function can solve alone: the ones that arise when moving life-saving products from development to patients.

Her career reflects a deliberate journey across science, technology, and business. A Ph.D. in Electrical Engineering from Notre Dame, where her nanophotonics research pioneered infrared medical devices, gave her the technical rigor to work at the limits of hard problems. Years in life sciences strategy consulting and incubator environments sharpened the market instincts that now define her approach to AI deployment in large pharma.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Recognized with BMS's Business Insights & Technology Innovation Award, Junchi and her cross-functional team drove measurable business value through AI-enabled supply chain analytics — bridging clinical, commercial, and operations stakeholders around a shared strategic vision.

She leads Sino-American Pharmaceutical Professionals Association (SAPA)'s Global Communication team, has hosted 30+ episodes of the SAPA 8@8 career series, and delivered 10+ AI workshops helping practitioners cultivate their "Edge" collaboration.



Lan Luo, PhD
Assoc. Prin. Scientist,
Biostatistics,
Merck

Lan Luo is an Associate Principal Scientist in Biostatistics and Research Decision Sciences (BARDS) at Merck & Co., Inc., where she supports early- and mid-stage oncology development. She serves as co-program lead statistician on early oncology assets and as trial lead statistician across the development lifecycle, from first-in-human dose-finding design through interim analyses, clinical study reports, and regulatory submissions in the United States, European Union, and Japan, including filings that supported a biomarker-based approval. She is also the standing due diligence statistician for early oncology business development, having led nine in-licensing evaluations, work recognized with Merck Research Laboratories' Pipeline Award for Innovation and Scientific Excellence. Much of her current effort goes to building GenAI-enabled tools that automate oncology analysis and reporting while preserving quality control, source traceability, and reproducibility. Her methodological research spans concentration-QTc assessment in early oncology trials, adaptive Phase 2/3 designs, and statistical methods for large-scale genetic studies, with work published in Nature Communications, Biostatistics, and Briefings in Bioinformatics. She holds a Ph.D. in Statistics from the University of Wisconsin-Madison.



Sho Islam
Director Office of Business Engagement
Department of Economic Development
Middlesex County, New Jersey

Sho Islam serves as the Director of Middlesex County's Office of Business Engagement (OBE), where he leads strategic initiatives to strengthen the county's business landscape and advance economic growth. Through close collaboration with industry leaders, entrepreneurs, academic institutions, and public-sector partners, he champions initiatives that drive innovation, investment, business growth, and long-term economic prosperity across Middlesex County and New Jersey.

A passionate advocate for New Jersey's innovation ecosystem, Sho serves on the Advisory Boards of the New Jersey Bioscience Center, the state's largest life sciences incubator, and the Rutgers Food Innovation Center, a globally recognized hub for food innovation and commercialization. He also serves as Membership Committee Chair for the Middlesex County Workforce Development Board. Before joining Middlesex County, Sho served as a Business Advocate with the New Jersey Department of State's Business Action Center (NJBAC). He previously served as Director of Business Development at Advance Connecticut (AdvanceCT), where he pioneered the organization's business retention and attraction strategies for the life sciences sector. As a Business Development Officer at Choose New Jersey, Sho led domestic and international business attraction efforts across multiple industries.

Sho began his career at Rutgers University's Food Innovation Center, where he developed expertise in business development, entrepreneurship, innovation commercialization, strategic business consulting, and project management. Sho holds a Bachelor of Science (BS) in Environmental Business Economics, a Master of Science (MS) in Food and Business Economics, and a Master of Science (MS) in Public Affairs, all from Rutgers University.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Caroline McGregor, PhD
VP, Pharm Analysis
& Digital Technologies
Merck & Co.

Caroline McGregor leads Pharmaceutical Analysis & Digital Technologies at Merck. In this role she leads analytical method development and validation for release and stability for small molecule, as well as analytical characterization, microbiology and compliance across modalities and this work enables process and product understanding from Discovery through commercial launch. She is also leading a comprehensive, multi-year digital transformation across CMC to meet the growing demands of a dynamic pipeline, increase development speed and robustness, and expand organizational capacity, an effort anchored by a multi-million dollar investment from 2025–2029 to modernize the full CMC value chain. She holds a Ph.D in Chemistry from the University of Cambridge and has been with Merck for 25 years, based in Rahway, New Jersey.



Amy Spinney, MBA
Global Director of Product Management,
Fresenius Medical Care

Amy Spinney is a first-generation immigrant whose career spans China and the United States. Drawing on that experience, she helps leaders unlock their potential, strengthen their personal brands, and break through the invisible barriers that can limit their growth.

Amy is the Founder of Unstoppable Coaching and a John Maxwell Leadership Certified Coach, Speaker, and Trainer. Her perspective is grounded in experience: she has spent more than two decades in MedTech and Life Sciences, built and operated her own coaching business, and advised organizations on B2B growth across U.S. and international markets. She holds an MBA from Boston University and a bachelor's degree in biomedical engineering from Tianjin University.



Blake Salisbury
SVP Global Business Development
Innovent Biologics

Mr. Blake Salisbury is Senior Vice President, Business Development at Innovent Biologics. With nearly 35 years of experience in the pharmaceutical and biotechnology industry, he has played a central role in shaping Innovent's evolution into a globally integrated biopharmaceutical company.

Over the past decade, Mr. Salisbury has led or played a key role in more than 40 strategic collaborations with multinational pharmaceutical companies and leading China and regional biotech innovators, helping position Innovent at the forefront of cross-border drug development and commercialization. His work has focused on building long-term partnerships that leverage China's development speed and scale to accelerate global innovation.

He led Innovent's landmark partnership with Takeda Pharmaceuticals — one of the largest cross-border transactions between a China-based biopharmaceutical company and a global innovator — establishing a new model for shared development, profit participation, and co-commercialization. He also played a key role in advancing Innovent's recent multi-product collaboration with Eli Lilly spanning discovery through proof-of-concept development in China. Then a few months ago, he also led a 12-product transaction with Pfizer in Oncology, further establishing Innovent as an Innovation leader in China. In 2021, he led the in-licensing of Mazdutide from Eli Lilly for China development and commercialization, a therapy with the potential to become China's leading obesity product.

Prior to joining Innovent, Mr. Salisbury spent nearly 24 years at Eli Lilly and Company, where he completed more than 50 transactions across research, development, and commercial-stage assets. He received his MBA from the Thunderbird Graduate School of Global Management.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Zhen Ma, PhD
Director,
CMC management,
Wuxi Biologics

Dr. Zhen Ma has over 13 years of experience in the biotechnology industry with expertise spanning molecular biology, biochemistry, and process development. In his early career, he served as a scientist in the DuPont Nutrition & Bioscience division (now part of IFF), developing microbial strains for industrial enzyme manufacturing. He later became a group leader and then joined Ingredion as Senior Manager of the Biotransformation group to drive innovation for food & beverage ingredients. With the goal of extending applications of microbes in the pharmaceutical industry, Zhen joined Merck where he served as Director of a newly formed Novel Expression Systems group in the Process R&D department. He built and led a team of highly talented scientists to develop next-generation microbial platforms for biomolecule expression to support early- and late-stage programs. Recently, Zhen joined WuXi Biologics as Director in the global CMC management team to provide CMC leadership for clients and support the operational strategy alignment of internal efforts with client product development goals and regulatory guidelines. Zhen holds a Ph.D. in Biochemistry from Texas A&M University and a B.S. in Biological Sciences from Fudan University. He completed his postdoctoral training at Cornell University.



Eric Rong
CEO
Rysteril Biopharmaceuticals

Possesses over 30 years of experience in pharmaceutical R&D and operations, spanning sterile injectables, ophthalmic preparations, solid and semi-solid dosage forms, complex sustained-release generics, 505(b)(2) drugs, and innovative medicines. Extensive hands-on experience in technology transfer, scale-up, manufacturing, quality control, regulatory affairs, CRO/CMO management, business development, and commercialization in the North American market.

Led or participated in the development and regulatory filing of over 40 innovative drug and formulation projects; successfully steered more than 100 sterile products (ANDA and 505(b)(2)) from initial R&D through to US market approval.

Served as Head of Formulation R&D for a NASDAQ-listed company and as Founder, CEO, or President of multiple US

pharmaceutical firms, with comprehensive responsibility for R&D strategy, operations, fundraising, pipeline management, and business development.

Founded Klus Pharma in New Jersey, establishing R&D laboratories for both small molecules and large-molecule biologics; built a team of approximately 50 employees and secured around \$50 million in investment.

Graduated from the School of Life Sciences at Peking University.



Victor Sun, PhD
Executive Director, Research
Platform,
Innovent Biologics

Victor obtained his Ph.D. in Biomedical Engineering from UCLA. Since then, he has worked in the US pharmaceutical industry for 18 years with focus on large molecule discovery and engineering at Abbvie, Sanofi and Jackson Laboratory. Currently Victor is an executive director and the head of antibody discovery and protein engineering at Innovent Bio based in Suzhou, China.



Bingxin Shen, PhD
Director, AI Solution Delivery, Business
Insights & Technology,
BMS

Bingxin Shen is Director, AI Solution Delivery within Business Insights & Technology at Bristol Myers Squibb, where she leads agile transformation of enterprise AI Accelerator initiatives spanning R&D, Manufacturing, Commercialization, and Finance. Bing began her career as a research scientist in cryo-EM and machine learning at Columbia University Medical Center and Howard Hughes Medical Institute, then pivoted into industry, scaling Agile and AI transformation across global teams in the US, Germany, and Japan. At BMS, Bing has led AI/ML initiatives across data strategy, digital marketing, and revenue forecasting, and has trained hundreds of stakeholders on Agile and AI-enabled ways of working. She holds a Ph.D. in Machine Learning and Computer Engineering from Stony Brook University. Bing is also a builder of community: she co-founded "Let's Meet," an internal networking platform that scaled to 13,000+ BMS colleagues, and serves as STEM Co-Lead of the Pan Asian Network, leading scholarship and mentorship programs for early-career professionals navigating STEM career paths.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Yue Shentu
Associate Vice President
Merck & Co.

Yue Shentu is an associate vice president of biostatistics and therapeutic area head for late development statistics oncology at Merck & Co. He oversees the statistical strategy and executions for the development of clinical portfolios in thoracic malignancies, head and neck squamous cell carcinoma, and gastrointestinal cancers.

Beyond his day-to-day work, Yue leads the American statistical association Biopharmaceutical Section's AI/ML Working Group, where he has driven the development of ontologies and benchmarks for enabling and evaluating AI copilots in trial design and analysis.



Sherry Song, PhD
Principal Scientist, Merck

Sherry Song is a Principal Scientist at Merck's regulatory CMC department and is responsible for developing regulatory CMC strategies for projects from First-in-Human (FIH) studies to post-approval commitments.

Sherry holds a B.S. in Chemistry from University of Science and Technology of China (USTC) and Ph.D. from Texas A&M University. With over 25 years of experience at Merck, Sherry has contributed to the development and commercialization of various products. In addition, Sherry served as the 2023 Chair of the Analytical Leadership Group (ALG) within the International Consortium for Innovation and Quality (IQ) and the 2024-2025 co-lead of Merck's Asia Pacific Association (APA) NJ chapter.



Jens Sydor, PhD
Vice President, DMPK
GSK

Dr. Jens Sydor is Vice President, Drug Metabolism and Pharmacokinetics at GSK. His global DMPK organization supports the whole GSK pipeline from early Discovery to post-submission. The main focus is on Discovery in vitro/in vivo ADME science,

mechanistic in vitro/in vivo ADME studies, translational PKPD and PBPK modeling for the prediction of human outcomes. During his career in the biotech/pharma sector since 1999, Jens has contributed to the discovery and development of several pharmaceutical products as well as leading many organizations successfully through change. He has also been a longstanding member of the IQ TALG, holding the vice-chair and chair position from 2019-2022.

Jens received his Ph.D. from the Max-Planck-Institute for molecular physiology in 1998.



Carla Lema Tome, PhD, MBA
VP of Business Development
Otsuka Pharmaceutical US

Carla Lema Tomé is a VP of Business Development at Otsuka Pharmaceuticals, working globally with colleagues in Japan and Europe and leading the US based team. In this role, she and her team are responsible for the global search, scientific evaluation, business case preparation and negotiation of assets, research programs and platforms from early research to late clinical development and commercial stages. She was previously at Spark Therapeutics, a member of the Roche group, as Senior Director of Business Development focusing on Neuroscience, Ocular, and Platform Technologies opportunities. Carla has had roles as a Commercial and Medical Strategy consultant and as Therapeutic Strategy Lead working with pharmaceutical and medical device companies focused on the CNS space to develop integrated clinical development plans, evaluating assets and markets, and supporting launch planning. Carla has a PhD in Neurobiology and Anatomy and an MBA, both from Wake Forest University and has completed two postdoctoral fellowships in the Brain Tumor Center of Excellence at Wake Forest School of Medicine, and in the Department of Experimental Medicine at Lund University. Carla maintains an Adjunct Assistant Professor's appointment at Wake Forest School of Medicine where she lectures on neurotech commercialization, developmental neuroscience, and regulatory affairs.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Matteo di Tommaso
SVP, AI & Digital Technology
Bristol Myers Squibb

Matteo joined Bristol Myers Squibb in 2022 to lead technology strategy and operations for the company's drug development organization. Matteo is passionate about transforming patient lives through digital technology, information, and productive partnerships. Prior to joining BMS, Matteo built a proven track record of delivering successful technology products and services, enterprise transformations and new capabilities at Pfizer, Biogen, and Sanofi. He has also worked in smaller organizations building innovative technology and data products and services for the European Bioinformatics Institute, Genetics Computer Group and Celera Genomics. He has led cross industry as a founder and chair of the PRISME forum and working on cross-pharma initiatives from roles in R&D and Medical IT, CIO and CTO.



Ming Tang, PhD
Director, AstraZeneca

Ming Tommy Tang is a computational biologist with over 14 years of experience in genomics, epigenomics, and single-cell transcriptomics. He earned his PhD from the University of Florida in 2014, trained at MD Anderson, and held non-tenure-track faculty roles at Harvard and Dana-Farber. At AstraZeneca, he leads epigenetics bioinformatics for oncology. A former wet-lab biologist, Tommy is passionate about open science and helping biologists gain computational skills. With over 140K followers across social media platforms, he aims to transform bioinformatics education. Learn more at divingintogeneticsandgenomics.com.



Vincent A. Vietti
Office Managing Partner (Princeton)
and Co-Chair of Public Companies
Practice
Fox Rothschild LLP

Vincent A. Vietti is a Partner at Fox Rothschild LLP and serves as Managing Partner of the firm's Princeton, New Jersey office and Co-Chair of its Public Companies Practice. He is an experienced corporate and securities attorney who acts as outside general

counsel to numerous small- and mid-sized public and private companies. Vince advises clients on a broad range of transactional and corporate finance matters, including structuring, negotiating, and closing mergers and acquisitions; securing venture capital investments; and completing public and private securities offerings. He also counsels clients on compliance with federal and state securities laws, corporate governance, and negotiating complex commercial contracts such as supply agreements, licensing arrangements, and joint ventures.

Over the course of his career, Vince has worked extensively with companies across the pharmaceutical, medical device, biotechnology, software, logistics, defense, and cannabis industries, among others. Prior to attending law school, he gained hands-on capital markets experience as a registered sales representative with a Wall Street investment bank. Vince earned his J.D. from Temple University School of Law and his B.S., magna cum laude, from Temple University. He is admitted to practice in New Jersey and Pennsylvania, and has been recognized in Best Lawyers in America for International Mergers and Acquisitions.



Thiru Venkatachalam
Vice President & Senior Partner
Enterprise AI Transformation Leader
IBM Consulting, Americas

In his role, Thiru leads a global team of senior professionals specializing in Agentic AI and hybrid cloud technologies, focused on delivering production-grade AI solutions for complex enterprise environments.

Thiru brings deep technical and architectural expertise across AI systems, generative AI, enterprise software, mainframes, Red Hat and VMware platforms, ERP systems, custom application development, and hybrid multi-cloud environments spanning IBM Cloud, Azure, AWS, and GCP. His industry experience includes technology, consulting, telecommunications, media and entertainment, automotive, oil and gas, energy, utilities, and manufacturing.

Previously, Thiru held senior leadership roles across hybrid cloud service lines, strategic partnerships with hyperscalers, global delivery, enterprise architecture, and core technology functions.

Beyond IBM, Thiru is committed to community service and volunteers at his local food bank alongside family and friends. He also enjoys traveling, playing tennis, and exploring astronomy.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Tianhao Wu, PhD
Founder & Chief Humanity Officer
OPAIDA, Inc

AI veteran and technology innovator with a track record spanning enterprise AI, intelligent automation, and large-scale digital transformation. Has implemented 200+ AI use cases and pioneered technology to mitigate AI model hallucinations. Previously selected by the IRS as the sole vendor to process 500M+ paper tax returns and served as a global AI automation supplier to Bank of New York Mellon. As a platform architect at WorkFusion, helped drive the company to a #1 industry ranking in Intelligent Document Processing.

An early AI pioneer, he developed an AI-driven Q&A search engine in 2007. He holds a PhD in AI from Lehigh University and is an Outstanding Graduate of Peking University.



John Wang
SVP & CSO
Gan & Lee Pharmaceuticals

John Wang is the Senior Vice President and Chief Strategy Officer (SVP & CSO) of Gan & Lee Pharmaceuticals, overseeing the company's business development and strategic collaborations, spearheading Gan & Lee's global expansion and portfolio diversification across multiple therapeutic areas.

Dr. Wang brings over 30 years of distinguished experience in the pharmaceutical industry, spanning R&D, corporate strategy, and commercialization. He possesses a proven track record in business development, including in-licensing, out-licensing, and alliance management. His expertise covers the entire lifecycle of strategic growth—from early-stage project evaluation and due diligence to cross-functional execution and global implementation.

Dr. Wang holds a Ph.D. in Pharmacology from the University of London and conducted postdoctoral research at Harvard University and Boston University School of Medicine. This robust scientific foundation is paired with a visionary approach to industry trends. His career began at Wyeth Pharmaceuticals, initially focusing on R&D in neuroscience and CVMD fields. He subsequently transitioned to business development and strategic partnerships, holding leadership roles at global pharmaceutical leaders including Sanofi, Merck, Eli Lilly, and Simcere Pharmaceutical Group. Over the course of his career, Dr. Wang has led or facilitated strategic collaborations and investments with a cumulative value exceeding USD 10 billion, demonstrating exceptional capabilities in resource integration and strategic execution.



Jin Wang
Endowed Professor in Pharmacology & Director, Center for NextGen Therapeutics, Baylor College of Medicine

Dr. Jin Wang is currently the Michael E. DeBakey, M.D., Endowed Professor in Pharmacology and the Director of Center for NextGen Therapeutics at Baylor College of Medicine. Dr. Wang's research centers on chemistry and serves biology, spanning from chemical biology tools and method development to rational design of therapeutics, including small molecule inhibitors, protein degraders, and antibody-drug conjugates. He built a highly integrated biotech-like academic drug discovery group with expertise including high throughput docking, MD simulations, AI-based protein folding, medicinal chemistry, biochemical and cell biology assays, high throughput proteomics, in house DMPK assays, and animal models for therapeutic efficacy testing.



Lu Xu, MBA
Executive Director
Global Business Development and Marketing
Altruist Biologics

As the Executive Director of Global Business Development and Marketing, Lu Xu oversees business development and marketing initiatives. Prior to this role, Lu Xu led project management, lean operation, and supply chain initiatives. Her background includes diverse leadership roles in supply chain, operational excellence, and third-party management at GSK and Abbott. With this extensive experience, Ms. Xu brings valuable expertise to drive the company's expansion and strategic partnerships at Altruist Biologics. She holds a Bachelor's degree from the China Pharmaceutical University and a Master of Business Administration from the University of Paris.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Jun (Stephen) Xue, MS
Stephen Xue, MS
General Manager, ThalassaX
Therapeutics US

Jun (Stephen) Xue is the General Manager of ThalassaX Therapeutics US Ltd. /Chipscreen Bioscience (US) Ltd. As the first employee of Chipscreen Bioscience (US) Ltd., a wholly owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SH), he oversees overall U.S. operations, staff recruitment, and coordination of clinical development and business development activities across internal teams and external partners.

Stephen brings more than 25 years of deep pharmaceutical industry experience, having held roles at Roche, Sanofi, Bristol Myers Squibb, Celgene, Galderma, and Eli Lilly. He has contributed to multiple FDA NDA and European MAA submissions across immunology, oncology, dermatology, diabetes, and cardiovascular disease. He also has several years of biotech investment experience, including participation in investing activities for companies that later achieved IPO on the Hong Kong Stock Exchange.

Before relocating to the United States, Stephen was part of the first generation of Merck China employees, beginning his career in sales and marketing before advancing into global roles.



Jianda Yuan, MD, PhD
Senior Medical Director
Merck & Co.

Dr. Jianda Yuan is an oncology surgeon and tumor immunologist with more than 25 years of experience in cancer immunotherapy. As Director of the Neoadjuvant/Adjuvant Working Group and Co-Director of AI Imaging at Merck Research Laboratories, he provides strategic leadership for late oncology clinical development especially in head & neck and cutaneous squamous cell carcinoma. His work spans the full development lifecycle—from early-phase clinical programs to late-phase strategy and regulatory planning—and he leads global registration studies through complex FDA interactions, from INDs to pivotal filings, proactively resolving operational challenges to meet timelines. Dr. Yuan directs Head & Neck and Lung PDT efforts across a broad portfolio (including KN122, KN161, KN495, KN629, KN630, KN689, LEAP-09, V940-007,

MK-3475-D46, and MK-3475-D77). He recently completed Harvard Medical School's "AI in Health Care" program, reflecting his commitment to integrating advanced computational tools into clinical development.

Dr. Yuan earned his MD and PhD from Fudan University Shanghai Medical College and completed a postdoctoral fellowship at Columbia University. During his subsequent 14-year tenure at Memorial Sloan Kettering Cancer Center as Director of Immune Monitoring and a Ludwig Center faculty member, his scientific foundation was profoundly shaped by the privilege of being trained by Dr. Lloyd Old, the "Father of Modern Tumor Immunology," and 2018 Nobel Laureate Dr. James Allison. A recognized innovator holding patents for novel technologies and treatments, he is committed to the broader medical community. He chaired the SITC Biomarker Committee, co-chairs the CAHON Industry Committee, and is an Associate Editor for the Journal for ImmunoTherapy of Cancer since 2013. With approximately 80 peer-reviewed articles in prestigious journals like Science, NEJM, and Nature Medicine, he remains an active member of ASCO, AACR, ESMO and SITC.



Song Yang, Ph.D
Senior Research Investigator
Arvinas

Song Yang is a computational chemist with eight years of experience applying structure-based modeling and machine learning across small molecules, biologics, targeted protein degraders, and antibody-drug conjugates.

As Senior Research Investigator at Arvinas, he leads structure-based ligand discovery for novel protein targets. He established AI-driven virtual screening workflows with Schrodinger and Chemprop that identified highly potent ligands, designed novel E3 ligands now used across pipeline projects, and applied RDKit cheminformatics to identify potent degrader building blocks.

Previously at Merck Research Laboratories, where he rose to Senior Scientist II, he applied AlphaFold-predicted structures to ligand optimization, redesigned an antibody with Rosetta to yield a tetra-mutant with improved antigen affinity, built ML-based ADMET prediction models, and implemented deep-learning generative models for lead design. He also organized the department's monthly machine learning working group.

Song holds a Ph.D. in computational chemistry from UCLA and

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

a B.A. in chemistry from Fudan University. He is an author on more than twenty publications and patents, and serves as an industry mentor in the NSF I-Corps program. His work is driven by a single goal: making drug discovery more efficient and reversing Eroom's Law.



Zhiwei Yin, PhD
Associate Director, Bristol Myers
Squibb

Zhiwei Yin is an Associate Director on the AI for Clinical Development (AICD) team at Bristol Myers Squibb, where he designs and deploys multi-agent AI systems that guide decision-making across clinical trial operations and business development. His current work spans enrollment forecasting, study design intelligence, and competitive intelligence — with hands-on experience deploying agentic systems in production with end-to-end AI observability and tracing. Before focusing on clinical development, Zhiwei built the recommender engine supporting HCP engagement for commercial applications, which earned BMS's enterprise BI&T Impact Award. Outside BMS, Zhiwei serves as Chair of the SAPA (Sino-American Pharmaceutical Association) Data Science Community, a non-profit dedicated to delivering cutting-edge AI topics grounded in pharmaceutical use cases.



LunHsiang Yuan, MD, PhD
Deputy Director, urology Department
National Taiwan University Hospital

Dr. LunHsiang Allen Yuan is Deputy Director of the Department of Urology at National Taiwan University Hospital, Yunlin Branch, and Adjunct Assistant Professor at the College of Medicine, National Taiwan University. A urologic oncologist and robotic surgeon, he also holds a Ph.D. in artificial intelligence, with prior practice at Taipei Veterans General Hospital, Kaohsiung Veterans General Hospital, and E-Da Cancer Hospital.

A practicing physician-scientist, Dr. Yuan is dedicated to applying AI across three domains: drug development, medical education, and small business. He founded Apex AI Institute, a U.S. 501(c)(3) nonprofit advancing AI research and education, and co-founded its spin-out OncoLattice Bio to accelerate AI-driven oncology drug development. His work bridges frontline clinical insight with AI engineering, connecting Eastern innovation with Western drug development.



Yi Zhang
Director Member, CDI, HMH;
Co-leader, Cancer Immunology
Program, GLCCC

Dr. Zhang's career has centered on immune cell biology, the pathophysiology of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and cancer immunology, culminating in novel strategies to improve the safety and efficacy of cancer immunotherapies. As a director member at the Center for Discovery and Innovation (CDI), Hackensack Meridian Health (HMH), and co-leader of the Cancer Immunology program at Georgetown Lombardi Comprehensive Cancer Center (GLCCC), my work translates this expertise into new approaches for enhancing cancer immunotherapy and treating alloimmunity. My laboratory has consistently produced groundbreaking findings in T cell immunity, including identifying EZH2's roles in T cell regulation, GVHD, and antitumor activity; uncovering transcriptional regulators and cell death molecules that sustain pathogenic T cells; and identifying inflammatory DC subsets that direct pathogenic T cell responses. We have developed clinically relevant strategies to manipulate the immune system, effectively treating severe inflammatory diseases like GVHD while boosting tumor control via CAR-T cell therapy. This work has yielded 6 patents and 100 peer-reviewed papers in high-impact journals (Cell, Nature Medicine, Nature Immunology, Blood, JCI, Molecular Therapy, JI, etc.).



Le Zhan, Ph.D.
Partner
YUNION Healthcare Ventures

Le is currently Partner at YUNION Healthcare Ventures, a life-science-focused venture capital firm based in Shanghai, China. Le currently heads the investment team focusing on innovative therapeutics at YUNION. Le's investment portfolio includes (but not limited to) BioNova Pharmaceuticals, Duality Biotherapeutics (HK: 09606), Yoltech Therapeutics, Full-life Technologies, etc.

Under the leadership of former SAPA President Dr. Xiaodong Chen, Le co-founded the SAPA Healthcare Investment Forum and Roadshow and previously served as its Co-Chair.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Dan Zhang, MD, MPH

CSO of Peking Union Innovation Hub
Co-Chairman & Co-founder of
Hillgene Biopharma

Zhang Dan holds a medical doctorate from Peking Union Medical College and furthered his studies at Harvard University and the Wharton School. He currently serves as a tenured professor at Fudan University and the Chief Scientist of the "Union Innovation Hub." He is a scientist and successful entrepreneur with an international perspective, having founded several biopharmaceutical companies. These include the international CRO firm Fountain Medical Development (now renamed ClinChoice), the CGT-focused CDMO firm Hillgene Biopharma. His ventures cover the entire industry chain of R&D, production, and services. He has been deeply involved in advising on and reviewing national pharmaceutical industry policies and previously served as an evaluation expert for the "13th Five-Year Plan" Major New Drug Innovation Program and as an ICH expert. He has been honored as a Forbes China Industry Development Leader in 2025, continuously driving innovation and development in China's biopharmaceutical sector.



Yingchao "YZ" Zhang, PhD
CO-FOUNDER & CHIEF AI OFFICER,
opAlda

Dr. YZ (Yingchao Zhang) is a highly respected Chinese American community leader on the U.S. East Coast, a serial entrepreneur, and an innovative practitioner in the field of artificial intelligence. He brings more than two decades of experience spanning systems administration, cybersecurity, software engineering, and AI innovation. He currently serves as Co-founder and Chief Operating Officer of opAlda.ai, where he is dedicated to advancing enterprise AI solutions and driving their successful deployment in real-world industry applications. He holds a Ph.D. in High Energy Nuclear Physics from the State University of New York at Stony Brook and a bachelor's degree in Low Temperature Physics from the University of Science and Technology of China. Beyond his accomplishments in technology and business, Dr. YZ is also regarded as one of the pioneers of Chinese American public service leadership in the United States.



Blair Bu

BMgt, Senior Partner,
Life Science & Healthcare,
IntelliPro

Blair Bu is the Global Senior Partner for Life Sciences and Healthcare at IntelliPro Group, where she leads a dynamic team of over 100 professionals across various regions and countries. With more than a decade of experience in executive search, Blair has developed a deep expertise in the global healthcare sector, particularly in pharmaceuticals and medical devices. Her strategic acumen has facilitated significant



Huanyu Chen

Sr. Computational Statistician
Eli Lilly

Huanyu Chen is a Senior Computational Statistician at Eli Lilly and Company, where she supports the statistical analysis and reporting of clinical trials, with a current focus on neuroscience. Her work includes clinical trial data analysis and regulatory deliverables. She holds a Master of Science in Biostatistics from Columbia University. Her professional interests include clinical trial methodology, statistical computing, and the application of data-driven approaches to drug development.



Wei Ding, PhD

Senior Director, Bioinformatics,
Data Science, and AI, AstraZeneca

Dr. Wei Ding is the Head of Bioinformatics, Data Science and AI at AstraZeneca Rare Diseases. With more than two decades of experience in the healthcare industry, he has led data science and translational medicine efforts to advance drug development and clinical research. Prior to AstraZeneca, he served as VP of Data Science at Dotlab, CSO and Head of Research at Admera Health, Clinical Genomics Lead at Mount Sinai, and Principal Scientist at Schering Plough/Merck. He has also been an adjunct professor at Kean University and has published over 60 peer-reviewed papers and patents.

Dr. Ding obtained his Ph.D. in Biophysics from the State University of New York at Stony Brook, and B.S from the University of Science and Technology of China.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

Biographies of Session Chairs and Moderators



Yong Guo, PhD, MBA
Professor of Pharmaceutical Science
College of Pharmacy and Health Sciences
Fairleigh Dickinson University

Dr. Yong Guo is currently Professor of Pharmaceutical Science and Chair, Department of Pharmaceutical Sciences at the School of Pharmacy and Health Sciences, Fairleigh Dickinson University (FDU). Dr. Guo holds a Ph.D degree in Chemistry from the State University of New York at Buffalo as well as a MBA degree in Pharmaceutical Management from Fairleigh Dickinson University. As a founding faculty member, he has made significant contributions to the establishment and accreditation of the Doctor of Pharmacy (Pharm.D) program at FDU. Prior to his academic career, Dr. Guo spent almost 15 years in drug development in the pharmaceutical industry and contributed to the development and regulatory approval of several innovative drugs. Dr. Guo's research interest includes chromatographic theories, in-vitro drug release, drug stability and quality assessment.



Brian Jiang
Digital & AI Solution Lead at Pfizer

Brian Jiang is a senior digital engineering and artificial intelligence leader with extensive experience delivering enterprise-scale solutions across pharmaceutical and biopharma research and development organizations. As his current role at Pfizer, he leads the design and implementation of AI-powered platforms, cloud solutions, automation workflows, and scientific applications that support clinical research, drug development, knowledge management, and operational efficiency. Throughout his career at Pfizer, Regeneron, Teva, and Hikma, Brian has led complex initiatives involving AI/ML, global platform deployments, R&D informatics, infrastructure migrations, workflow automation, and regulated systems.



Lily Li, PhD
Associate Professor, UHart

Dr. Lily Li is a Cell and Developmental Biologist with over 30 years of experience in biomedical research, academia, STEM leadership, and community engagement. A central focus of her career has been connecting the dots between academic research and the biomedical industry—bringing together scientific discovery, emerging technologies, industry needs, and collaborative networks to accelerate translation and real-world impact. She has led statewide NASA STEM initiatives across 26 Connecticut institutions, managed multimillion-dollar grants, and held leadership roles in academic and nonprofit organizations. Her research has received national recognition, including a “Faculty of 1,000 Must Read” designation and the most-downloaded paper of the year in STEM CELLS.

Dr. Li earned her Ph.D. in Cell and Developmental Biology from Temple University. She has received multiple honors for excellence in teaching, research, and service and remains committed to mentoring the next generation of STEM leaders while strengthening connections among academia, biotechnology, and the broader biomedical ecosystem.



Shuai Li, PhD
Principal Scientist
Drug Product Development and
Technology
Regeneron Pharmaceuticals Inc.

Dr. Shuai Li is currently a Principal Scientist at Regeneron Pharmaceuticals, where he leads drug product development for pharmaceutical biologics, across antibody, bioconjugate, AAV and retargeting AAV gene therapy products. As a subject-matter expert in drug substance and drug product formulation, he designs and executes phase-appropriate formulation, compatibility, and stability studies, and serves as a program lead for technology transfer and drug candidate characterization to enable preclinical and clinical development. He has also driven technology development efforts,

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

including high-throughput automation platforms for drug product stability optimization, novel co-formulation approaches, and fit-for-purpose analytical methods. Dr. Li earned his Ph.D. from Duke University, where he researched the biosynthesis of chemical molecules in engineered *E. coli* through dynamic metabolic control and protein engineering. He has published more than 20 peer-reviewed works in journals including the Journal of the American Chemical Society, Metabolic Engineering, and the Journal of Pharmaceutical Sciences, and is a co-inventor on multiple patents spanning formulation and technology development. He is an active contributor to the gene and cell therapy community, serving as a session chair for the American Society of Gene & Cell Therapy (ASGCT) Annual Conference and as an executive council member of the Sino-American Pharmaceutical Professionals Association (SAPA).



Dr. Haiying Liu, PhD
Medicinal Chemist Director, CSL

Dr. Haiying Liu, PhD, is an experienced and motivated leader in clinical biomarker development, actively leading Clinical Biomarker Strategy and Execution across major pharmaceutical organizations. He has a proven track record of advancing biomarker strategies, developing clinic-ready biomarker assays, and successfully executing companion diagnostics (CDx). Throughout his career, David has navigated complex regulatory pathways and leveraged emerging technology platforms to drive portfolios of novel targets. Prior to his current role, he oversaw numerous end-to-end biomarker projects and high-stakes clinical trials at CSL, Johnson & Johnson, Biogen, and Merck. His therapeutic expertise spans a wide range of disease areas, including metabolic diseases, immunology, obesity, retinal disease, hypertension, diabetes, atherosclerosis, and oncology.



Qi (Alex) Song, PhD
Principal Scientist,
PREDICTIVE BIOLOGY & AI,
BMS

Qi (Alex) Song is currently a Principal Scientist of AI and Predictive Biology at Bristol Myers Squibb. His expertise in computational biology and AI is accelerating the early development of cell therapy and genomics research, with specific focus on building end-to-end solution for in-silico optimization of molecules. Qi completed his postdoctoral training at Carnegie Mellon University and obtained his PhD in Bioinformatics from Virginia Tech.



Xiaowei Sun
Senior Scientist,
Translational Medicine
Bristol Myers Squibb

Xiaowei Sun is a Senior Scientist in Translational Medicine at Bristol Myers Squibb. She works in the Material Science group, supporting biomarker assay development as well as PK/PD method development and validation. Her work ensures the delivery of high-quality reagents to advance diverse biomarker platforms, PK/PD method development, validation, and sample analysis. The group plays a critical role in bridging program transitions from discovery to clinical development. Before joining BMS, Xiaowei was a Senior Scientist at Frontage Laboratories, specializing in PK/PD LC-MS method development, validation, and sample analysis. She brings deep expertise in bioanalytical sciences and translational research, with a strong interest in connecting laboratory innovation to clinical application.

Xiaowei earned her Ph.D. in Biochemistry from Miami University, where she studied protein-ligand interactions, followed by a postdoctoral fellowship at The Ohio State University on multi-omics research in metabolic syndrome and obesity. Beyond her scientific work, Xiaowei has been active in SAPA since 2021, where she led the Communication Team (WeChat platform) before becoming Head of Membership in 2024. At BMS, she also serves as a Global Project Manager for the PAN organization, fostering collaboration and organizational development.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Yang Wang, PhD
Director,
Business Development,
Asymchem Group

Yang Wang is a business development leader in the biopharmaceutical industry, with extensive experience supporting drug development and strategic partnerships across CRO and CDMO organizations. She currently serves as Director of Business Development at Asymchem Group and previously held senior business development positions at Abzena, Medicilon, and Covance. Yang combines a strong scientific background with business and strategic expertise. She holds a PhD in Biology from Rutgers University and an MBA in Strategy & Leadership from Rutgers Business School.



Jack Wu, Ph.D., MBA
Associate Vice President, Head of
Search & Evaluation, Incyte

Jack Wu serves as Associate Vice President, Head of Search & Evaluation at Incyte, with more than 15 years of experience across the biotechnology and biopharmaceutical industries, spanning business development, external innovation, and strategic planning. Prior to joining Incyte, Jack held leadership roles including Senior Director, Business Development Search & Evaluation at Takeda Oncology, Head of Search & Evaluation at Antengene, and U.S. Head of Search & Evaluation at Adlai Nortye, as well as other positions across the biotechnology industry.

Jack holds an MBA from Columbia Business School and a Ph.D. in Biology from North Carolina State University.



Dr. Dexi Yang
Medicinal Chemist Director, QuantX
Biosciences

Dr. Dexi Yang got his BS and MS in Nanjing University. He received his PhD in Organic Chemistry from The Ohio State University, where he worked on the total synthesis of chaparrinone and polyandranes in Prof. David J. Hart's group. In 2009, he joined Prof. Glenn C. Micalizio's group at The Scripps

Research Institute in Florida as postdoctoral researcher and completed the total synthesis of alkaloid (-)-205B. After working at Dartmouth College, he joined Merck in 2014 as a medicinal chemist in Kenilworth, NJ. He has designed and synthesized many drug candidates, mainly in the areas of infectious disease, cardiovascular and CNS, and three compounds (MK-3866, MK-3402 and MK-6552) are in clinical stages. He resigned from Merck and joined QuantX Biosciences in 2023, where he has been leading several small molecule drug discovery projects covering broad areas such as oncology and autoimmune, and some compounds are already in clinical study. He has co-authored more than 30 publications, 20 patents, and several book chapters in Current Drug Synthesis and Chemistry and Pharmacology of Drug Discovery.



Jason Zhong
Senior Software Solutions Architect
at Tokio Marine

Jason Zhong is a Senior Software Solutions Architect at Tokio Marine with over two decades of experience in enterprise architecture, software modernization, and AI-driven innovation. He has led major modernization initiatives across healthcare, insurance, and finance, transforming legacy systems into scalable, cloud-native platforms and delivering cloud-based solutions that improved efficiency and reached millions of users. Earlier in his career, he pioneered SaaS solutions and model-driven enterprise frameworks that accelerated solution delivery and earned multiple industry awards. Jason holds an MBA in Finance from the University of Hartford, an M.S. in Computer Science from Western University, and a B.S. in Space Physics from Peking University. Certified in AWS Cloud, SAFe Agile, and Machine Learning, he continues to bridge enterprise architecture with emerging AI technologies to drive digital transformation.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World



Harris Zhang, PhD, MBA
Cofounder of Axela Biosciences,
Founder of PicoImmune

Dr. Linghua Harris Zhang is a co-founder of Axela Biosciences, a NJ company providing integrated services and solutions for drug discovery and translational development, biomarker testing and diagnostics..

As an immunologist, Harris brings experience in the discovery and development of innovative therapeutics, including small and large molecules, ADCs, and cell/gene therapies addressing unmet medical needs. At Axela, Harris leads a multidisciplinary team with expertise in advanced technologies to support biopharma and life science clients worldwide. With his leadership, Axela has contributed to numerous discoveries and translational programs while developing innovative products and solutions for research and clinical applications.

Prior to Axela, Harris founded PicoImmune, a company focused on ultrasensitive and multiplex biomarker testing for biopharma. Earlier in his career, he held positions at Celgene (now BMS) and was a CRI Postdoc in Cancer Immunology at MIT. Harris holds an MBA in BioPharma Management from Rutgers, a Ph.D. in Immunology and Pharmacology from Peking Union Medical College.

He is the author of > 40 peer-reviewed publications and an inventor on 10 patents. Harris is an active member of the Society for Immunotherapy of Cancer, American Association for Cancer Research, American Association of Immunologists, and an EC member of SAPA.

2026 SAPA Annual Conference

Navigating Dynamic Landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

SAPA Service Excellence Award

The following individuals have been selected by the President Office as the recipients of the 2026 SAPA Awards.

SAPA Distinguished Achievement Award

Li Chen

SAPA Presidential Service Excellence Award

Jack Wu

SAPA Distinguished Contribution Award

Caroline McGregor

SAPA Service Excellence Award

Jiangchao Chen, Xiaodong Chen, Sidi Chen, Xi Cheng, Fei Chu, Yong Guo, Brain Jiang, Kejie Li, Haiying Liu, Junchi Lu, Chuanwen Lu, Yongle Pang, Xiaowei Sun, Bin Xiao, Aiguo Xu, Stephen Xue, Zhou Yu, Xinjun Zhang

SAPA Special Recognition Award

Jessica Cao, Jiangchao Chen, Shihan He, Chenfei Huang, Xin Huang, Siyu Jiang, Shuai Li, Wendy Li, Yannan Liu, Liushan Liu, Feiyi Sun, Yang Wang, Zhiwei Yin, Danni Zhang, Yingchun Zhao, Anbo Zhou, Minzhu Zou

SAPA-CT Service Excellence Award

Ran He, Xin Huang, Huijuan Zhong, Yunli Zhang

SAPA-DC Service Excellence Award

Victor Liang, Xuan Xu, Yingxue Sun, Emma Luo

SAPA-GP Service Excellence Award

Lixia Yao, Chunjuan Song, Yali Liang, Jialie Luo, Jingwen Niu, Hao Sun

SAPA-MW Service Excellence Award

Jingdong Qin, Ying Liu, Wenan Qiang, Haipeng Cheng

SAPA-NE Service Excellence Award

Wenyu Wang, Bo Yan, Zhiyou Deng, Yan Tan, Jackson Yeung

SAPA-NC Service Excellence Award

Yuelong Guo, Yapei Zhang, Jian Ma, Jing Zhang

SAPA Corporate Sponsor Recognition Award

Altruist Biologics, Apeloa Pharmaceutical, Axela Biosciences, ACROBiosystems, Bristol Meyers Squibb, Chempartner, Fox Rothschild, HkeyBio, Innovent Biologics, IntelliPro, Jiuzhou Pharma, MedChemExpress, Merck & Co., Medicilon, Nona Biosciences, OpAlda, Protheragen, Shuimu Biosciences, Tigermed, Tofflon, THC Lawyers, Wilmington PharmaTech, Wiskind, Willingjet,

2026 SAPA Annual Conference

Navigating dynamic landscape, Shaping BioPharma
Future - Advancing Healthcare Innovation in a Transforming World

SAPA Corporate Sponsors

Strategic Partner



CMC Session Sponsor



Gold Silver Sponsors



* We sincerely thank Suzhou Shengjie for their support with the design and layout of the brochure.

If you would like to contact Suzhou Shengjie, please email shengjie@shengjiejituan.cn



Explore Our Products, Solutions, and Services!

BIOSYSTEMS
Acro

Discovery & Development

CMC-
Manufacturing

CMC-Quality Control

Preclinical Studies

Clinical Studies

ACROBiosystems is a global biotech leader providing recombinant proteins, kits, antibodies, and services to support drug development from discovery to clinic. Trusted by top pharma, we drive innovation and empower progress in biopharmaceutical research.



Recombinant Proteins

Target Proteins Fc Receptors Growth Factors Extracellular Matrix Proteins Universal Antibodies

Protein-conjugated Beads ...and more!

Assays & Kits

Inhibitor Screening Quantitative Biomarker Kits Residual Detection Kits ADC Conjugation TR-FRET Assay Kits

Flow Cytometry Assay Kits ...and more!

Solutions

ex vivo Cell Manufacturing Solutions Ready-to-use Organoids for Disease Modeling One-stop Cell Line Solutions

BsAb Development Solutions In vivo CAR-T Solution ...and more!

Custom Services

Custom GMP-grade Protein Service Cell Line Customization Service EUSA Service

Recombinant Antibody Development Service ...and more!

Call us

North America:
+1 800-810-0816 (Toll Free)

Asia & Pacific:
+86 400-682-2521

Email

order@acrobiosystems.com
order.kr@acrobiosystems.com

Web

www.acrobiosystems.com
kr.acrobiosystems.com

Every Molecule Has A Path Forward

Altruist Biologics is a reliable CDMO and subsidiary of Innovent Biologics providing integrated biologics development and GMP clinical and commercial manufacturing services. We support biotherapeutic programs at any stage from cell line development to aseptic fill-finish.

Guided by our mission to provide a path forward for every molecule, we are committed to creating value for our clients through tailored solutions and a reliable supply of high-quality medicines for patients.

Integrated, One-Stop CDMO Solutions

mAb, BsAb, MsAb, Fusion Protein, Recombinant Protein, ADC and more



CMC
Development



Drug
Substance
Manufacturing



Drug
Product
Manufacturing



Labeling &
Packaging



Quality Control
& Analytics



Regulatory
Support

**Delivering quality and expertise
with more than 150 IND/BLA
approvals globally and 2,000+
commercial batches.**



www.altruistbio.com

**DNA to IND
in 9 months**

**~12g/L
Titers**

**>80%
High Yield**

APELOA

CDMO SERVICES

TOP 5

CDMO in China

700+

Customers Globally

20

US FDA inspection

With 3 R&D centers in Boston, Shanghai and Hengdian, and Chemical Synthesis Capacity of 11,710 m³ plus BIO-Production Capacity of 7,380 m³. Apeloa enabling global clients in expediting the delivery of affordable medications.

8 Technology Platforms:

- Flow Chemistry
- Peptide
- Synthetic Biology & Biocatalysis
- High Potency Compound

...



Apeloa LinkedIn



Contact Us

info_cdmo@apeloa.com

Learn more →

www.apeloa.com





Accelerating Life Science Innovation, Drug Discovery & Translational Development

Partnership to Advance Innovation

AXELA BIOSCIENCES is a trusted CRO based in New Jersey, specializing in drug discovery biology, translational development, bioanalysis and CLIA testing to **ACCELERATE** the development of novel therapeutics and diagnostics.

Our Services



BioPharma Services in Discovery Biology & Translational Development


- High-throughput & Content Screening
- Ultrasensitive & Multiplex Immunoassays
- High-dimensional Flow Cytometry
- Systematic Immuno-monitoring
- Spatial Proteomics & Genomics



Diagnostic Services & CLIA Testing

- Biomarker Discovery, Validation and Quantitation
- IHC/IF/ISH, Multiplex Staining & Digital Imaging
- LDT & CDx Development
- Kit Production, Fulfillment and Distribution

Technical Advantages





At Bristol Myers Squibb, the work you do will help people prevail over serious diseases. This isn't easy work, but it is uniquely interesting. This is where you will rewrite the rules, solve the toughest challenges, and create miracles.


It may just transform your career.



Join our talent community!

Scan QR code
and click Register.

This is where
transformations
happen.



©2025 Bristol-Myers Squibb Company. All rights reserved.
Bristol-Myers Squibb Company is an Equal Opportunity Employer.



From Discovery to IND: An Integrated Partner for Modern Drug Development

ChemPartner is a global CRO and CDMO providing integrated solutions across drug discovery, preclinical development, and GMP manufacturing. With more than two decades of experience and a team of 2,000+ scientists across chemistry, biology, pharmacology, and process development, we operate as an extension of our partners' R&D discovery programs. Our model brings together scientific execution with data-driven decision-making to improve program continuity, reduce development risk, and streamline timelines.

Integrated Capabilities Across the Drug Discovery Continuum

Discovery (Chemistry & Biologics)

We support a broad range of therapeutic modalities, including small molecules, monoclonal antibodies, bispecifics, ADCs, peptides, and oligonucleotides. Our chemistry teams integrate synthetic and medicinal chemistry with structure-based design approaches and AI-assisted prioritization tools applied to internal compound and assay datasets. Our biologics platform enables antibody discovery, engineering, and production – from target identification to development candidate selection.

Biology & Translational Pharmacology

Our biology platform bridges discovery and translation through integrated *in vitro*, *ex vivo*, and *in vivo* capabilities. We operate disease-focused capabilities across oncology, immunology, inflammatory, neuroscience, and metabolic diseases, we deploy validated assays (benchmarking against clinically approved agents) and advanced model systems – including CDX, PDX, and humanized models – to generate mechanistic insights and predictive efficacy data that guide decision-making from target validation to candidate nomination.

DMPK, Toxicology & Bioanalysis

Our integrated ADME, pharmacokinetics, and toxicology platforms support lead optimization and IND readiness. By combining *in vitro* and *in vivo* approaches with robust bioanalytical capabilities, we deliver regulatory-aligned data packages that de-risk candidate selection and enable confident progression into development.

CMC & CDMO for Biologics

We provide a seamless transition from discovery into development and manufacturing, including cell line development, process optimization, formulation, and GMP production. Our biologics manufacturing capabilities support scale-up from research-grade production through clinical-stage GMP batches, enabling continuity from discovery through IND and early clinical development.

Data-Driven and Translationally Focused

Our proprietary biology database integrates curated datasets across models, genes, pathways, and drug responses – enabling more informed model selection, smarter study design, and improved translational relevance. Combined with flexible execution and integrated analytics, we help partners reduce uncertainty and make faster, higher-confidence decisions across the development lifecycle.

A Scientific Partner

ChemPartner goes beyond execution. We contribute to study design, data interpretation, and strategic decision-making – aligning scientific, operational, and regulatory perspectives to accelerate timelines and reduce risk. Our collective model is designed for long-term partnership, supporting programs moving from discovery through IND submission with improved continuity of data, reduced fragmentation between stages, and enhanced decision confidence.

Strength in *science*. Flexibility in *partnership*.

Proud Supporter of 2026 SAPA Annual Conference



Always Thinking Forward

30 offices, coast to coast, we're committed to your success.

With you every step of the way, we make your challenges our own.

Innovative legal solutions to help you seize tomorrow's opportunities.

1000 attorneys with one priority: You.

Wansheng Jerry Liu, Ph.D., J.D.
Partner, Chair of China Practice
SAPA President 2019-2020
609.844.3037 | wliu@foxrothschild.com

Fox
Rothschild

Attorney Advertising



www.hkeybio.com



tech@hkeybio.com



Better Preclinical Decisions Before IND

Helping autoimmune and allergic disease teams turn preclinical studies into **Go / No-Go** decisions.



Target

Is the biology worth advancing?



Candidate

Which molecule should move forward?



NHP Strategy

When is NHP worth the investment?



HKeyBio integrates **disease-focused rodent and NHP models** with **pathology, biomarkers, flow cytometry**, and **PK/PD readouts** to support decision-ready evidence.



Let's discuss your next preclinical decision.

Our Purpose

Company Mission:

To empower patients worldwide with affordable, high-quality biopharmaceuticals

Development Strategy:


To discover new medicines through innovation and deliver them through our global platforms

Company Vision:

To be a premier global biopharmaceutical company



Shanghai Global R&D Center, China



Suzhou R&D Center, China



Fortvita Biologics, California

Growth Milestones in First 15 Years



20

commercial
products



42

clinical stage
candidates



140,000L

capacity in
operation



30+

global
partnerships



10,000

experienced
talents

MORE INFORMATION

www.innoventbio.com | www.fortvitabio.com



Innovent LinkedIn



Fortvita LinkedIn



Global Talent & HR Solutions Provider

ABOUT US



IntelliPro Group (IPG), established in 2009 in Silicon Valley, USA, is a leading provider of integrated HR solutions. IPG focuses on creating a global AI-driven talent platform, offering comprehensive HR services for enterprises expanding overseas, from recruitment to employment.

IntelliPro Bio, a division of IPG, specializes in tailored talent solutions, HR services, and consulting for the Life Sciences and Healthcare industries, including executive search, global expansion support, and investment and financing services.



MISSION

Committed to building a globally leading AI-driven platform for efficient talent matching and development.



VISION

Empowering global enterprises to thrive worldwide.

CORPORATE BUSINESS



Talent Solutions

Executive Search
RPO
Staffing



HR Solutions


EOR/PEO/HRO
HR Compliance
Global Mobility



Consulting Solutions

Global Expansion
Financial Advisory
Strategic Consulting

GLOBAL SERVICE COVERAGE



Preclinical → Phase I, II, III → Commercial

38
Innovative
drugs launched
globally



1000+
R&D Personnel
5000+
Employees



7
R&D sites
10
Manufacturing sites



693
EHS and GMP
audits and
Inspections



Integrated CDMO Services



Innovative Technologies

- Chiral Catalysis Technology
- Continuous Flow Technology
- Fluorine Chemistry
- Tag-assisted Peptide Synthesis
- Biocatalysis
- Photocatalysis
- Solid-State Research
- Separation Technology
- Spray Drying
- Sustainable & Green Chemistry
- Solvent Recycling



JiuZhou Pharma has once again been awarded the EcoVadis Gold Rating, reflecting our continued commitment to sustainability and strong ESG performance. We continue to work with global partners to build a more sustainable pharmaceutical value chain.



100,000+ Inhibitors & Agonists

Industry-Leading Bioinformatics

Target Coverage

1,500+ targets
20+ signaling pathways

Authoritative Support

In vivo / in vitro experimental
protocols from the literature

Dynamic Data

100,000+ solubility measurements
Clinical / approval tracking

Wide Applications

Pharmacology and biological
research, covering 400+ disease /
field studies, including cancer,
neurology, inflammation,
metabolism, stem cells, etc.

80,000+ Bioactive Molecules

Recombinant Proteins

ADC&PROTAC Peptides

Inhibitory Antibodies

Oligonucleotides

Robust Multi-Level Quality Control

International Standards



Complete Platform

400+ precision instruments,
300+ technical experts

One-Stop Drug Screening Platform

Screening Libraries

- Bioactive Screening Libraries
- Natural Product Screening Libraries
- Fragment Libraries
- Diversity Compound Libraries
- Virtual / AI Screening
- SPR Assay Service
- DEL Screening

Screening Services

Lead Compound Optimization

Easy-to-use Lab Tools

Reference Standards

Fluorescent Dyes

Antibodies Enzymes

High Efficiency Biological Kits

Isotope-labeled Compounds

Biochemical Assay Reagents

FREE SAMPLE APPLICATION



MedChemExpress USA

Tel: 609-228-6898

Fax: 609-228-5909

Address: 1 Deerpark Dr, Suite F, Monmouth Junction, NJ 08852, USA

E-mail: sales@MedChemExpress.com

Tech Support: tech@MedChemExpress.com

For research use only.
We do not sell to patients.

**Master of
Bioactive Molecules**

www.MedChemExpress.com



Medicilon is a one-stop preclinical CRO with over 20 years of experience, providing integrated drug discovery, CMC development, and preclinical research services spanning chemistry, biology, ADME/DMPK, pharmacology, safety assessment, and IND-enabling studies.

700+ IND approved by **FDA, NMPA, EMA, TGA, MFDS, PMDA**



• SERVICE SCOPE



Drug Discovery

- Chemistry
- Biology
- Early DMPK



Drug Development & CMC

- API/Formulation
- CMC Research




Preclinical Research

- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Drug Safety Evaluation
- Bioanalysis



IND Filing

- FDA
- NMPA
- EMA
- TGA
- MFDS
- PMDA



 : www.medicilon.com

 : info@medicilon.com

 : +1 (617) 888-9294

Address:

- 20 Maguire Road, Suite 103, Lexington, MA 02421(USA Corp)
- 585 Chuanda Road, Pudong, Shanghai, 201299(China)



Focused on patients. Driven by science.

Breakthroughs only matter when they reach the people they're made for.

Their needs shape our science, our decisions, and our solutions. From global programs to local partnerships, we're breaking down barriers and expanding access to the patients who need it most.

Explore how we're expanding access to lifesaving medicines at [merck.com](https://www.merck.com)





TRANSFORMING ANTIBODY DISCOVERY INTO THERAPEUTIC INNOVATION

From fully human antibody discovery to advanced therapeutic modalities,
empowering innovators to accelerate the development of transformative
medicines with greater confidence and precision.

CLINICALLY PROVEN FULLY HUMAN PLATFORM

Used in 300+ programs
and 19 INDs to deliver
fully human traditional
and heavy chain-only
antibodies.

NEXT GENERATION MODALITIES

Integrated technologies
to screen, optimize,
and engineer
antibodies for diverse
next-gen modalities,
enhanced by AI.

AI-ENHANCED, INNOVATIVE TECHNOLOGIES

Integrated platforms
to identify, optimize,
and advance
high-potential
therapeutics.

380+ Programs Supported
20+ IND/Clinical-Stage Programs Enabled
140+ Global Partners



**Learn About
Nona Biosciences**



DOCUMENT AUTOMATION



- Protocols
- Study Reports
- Regulatory Documents

REGULATORY SUBMISSIONS



- ✓ IND / NDA / BLA
- ✓ CSR
- ✓ CMC
- ✓ eCTD



QUALITY & COMPLIANCE

- GxP Aligned
- 21 CFR Part 11 Ready
- Full Traceability
- Audit Ready

AI-POWERED REGULATORY WRITING

FASTER. ACCURATE. TRACEABLE.

Generate accurate, consistent, traceable regulatory documents with AI.
Accelerate review and submission while keeping **experts in control**.

END-TO-END AI-ASSISTED REGULATORY WORKFLOW

1. SOURCE DATA



Collect and integrate structured & unstructured data from systems, studies and repositories.



2. AI-ASSISTED AUTHORING



AI generates first drafts, summaries and tables with citations and validation checks.



3. EXPERT REVIEW



Domain experts review, refine and approve with full control and transparency.



4. REGULATORY SUBMISSION



Deliver compliant submissions in eCTD format—ready for regulatory review.

WORKING WITH LEADING LIFE SCIENCES ORGANIZATIONS



FRONTAGE
LABORATORIES

And More...



UP TO 70%
Faster
Document
Review



HIGHER
Accuracy &
Consistency



LOWER
Review
Costs



STRONGER
Traceability &
Audit Readiness



**LET'S ACCELERATE
LIFE-CHANGING THERAPIES.**

Learn more or schedule a discovery call

www.opAlda.ai





Bridging Innovation with Global Opportunities, Driving BD Success

Headquartered in New York, Protheragen is a US-based company specializing in the global pharmaceutical and biotechnology fields. We are dedicated to providing our clients with exceptional business development and transaction intermediary services, helping companies with innovative assets to achieve breakthrough growth.

Core Services

Our core services aim to precisely connect innovative assets with potential partners worldwide, efficiently facilitating diverse strategic collaborations including, but not limited to:

- Out-licensing
- Co-development
- Equity Financing
- Mergers & Acquisitions

Protheragen has a dynamic and integrated team with deep industry insights, extensive international network, and exceptional execution capabilities.

Contact us to embark on your successful global business development journey.

Flexible Cooperation Model

We adhere to a flexible and efficient cooperation model, excelling at building wide-ranging industry connections, and actively facilitating in-depth collaborations among all parties.

- We are committed to providing asset owners with a financially stress-free and low-risk path to collaboration.
- To initiate cooperation, the asset owner simply needs to provide non-confidential materials (e.g., business plan deck) and agrees to let us introduce the assets to potential investors or partners.
- Given the complexity and challenges of cross-border transactions, to maximize cooperation efficiency, we prefer not to spend time discussing cooperation terms at the outset. Typically, we will negotiate specific terms and details once the third-party partner demonstrates a clear intent to collaborate.

🌐 www.protheragen.com

✉ inquiry@protheragen.com

📍 101-4 Colin Dr, Holbrook, NY
11741, USA



Shuimu Biosciences:

AI+Cryo-EM, For Future

PHONE | 400-886-2820
TELEPHONE | +1 (650) 680 9298
WEBSITE | www.shuimubio.com
EMAIL | hi@shuimubio.com

SHUIMU
BIOSCIENCES

9

High-end Cryo-EMs

4500+

Single Particle Projects

3200+

Determinations with Resolution Better Than 3.5Å

1.4 Å

Maximum Resolution

51kDa

Smallest Protein Downloaded

COMPANY INTRODUCTION

Founded in 2017 at Tsinghua University, Shuimu Biosciences operates the world's largest commercial cryo-EM platform. We are merging artificial intelligence with structural biology to provide a complete, one-stop solution for life science research and drug development.

OUR MISSION


To accelerate scientific innovation and clinical translation by delivering high-precision 3D protein structures, from gene sequence to atomic-level resolution.

WHAT PROBLEM DO WE SOLVE?

We eliminate the major bottlenecks in R&D:

- **Difficult Samples:** Analyze small, hard-to-crystallize proteins, membrane proteins, and flexible complexes without the need for crystals.
- **Slow Timelines:** Our automated, AI-driven platform accelerates structure analysis from months to just 7-14 days.
- **Drug Discovery Inefficiency:** Provide critical structural insights for vaccines, antibody drugs, and small-molecule development.

"One-stop" SPA Solution



linked in
Shuimu Biosciences



THC Lawyers and Innovanexus Consulting form an integrated professional services group serving the innovation economy.

Headquartered in New York and Toronto with five offices across North America, we deliver integrated legal, capital market, and technology services under one platform. With a focus on healthcare, AI, Fintech and energy industries, we support technology based companies and investors through every stage of the innovation lifecycle

Capital Markets

- Initial Public Offerings (IPO)
- Mergers and Acquisitions (M&A)
- Listing Preparation
- Post-Listing Compliance

Technology/IP Law

- IP Litigation and Dispute Resolution
- IP Commercialization and Transactions
- IP Prosecution and Management
- Data Protection and Privacy Compliance

Dispute Resolution

- Commercial and Contract Disputes
- Financial Disputes and Fraud
- Corporate and Shareholder Disputes
- Enforcement of Foreign Judgments

VC and PE Funds

- VC and PE Funds Formation
- Investment Assessment
- Startup Fundraising
- Post-investment Management Advisory

Corporate and Global Strategy

- Corporate Formation and Structuring
- General Corporate Legal Services
- Global Expansion Strategy
- Corporate Governance

Government Relationship

- Government Grant Applications
- Government Relationship
- Administrative Disputes and Litigation
- Regulatory Compliance

We integrate technology, law and capital
and deliver the growth for you

New York • Toronto • Silicon Valley
Washington DC • Vancouver

www.thclawyers.com
www.innovanexusconsulting.com





A Leading Global CRO for Biopharmaceutical Development

We partner with biopharmaceutical companies to turn scientific innovation into therapies that reach patients.

 www.tigermедgrp.com

 info@tigermедgrp.com

SCIENCE
FOR A HEALTHIER
TOMORROW

11,900+

 Employees
Worldwide

4,200+

 Customers
Worldwide

180+

 Locations
Worldwide

73+

 China Innovative
Drugs Supported

Across Asia Pacific, Europe, North America, Latin America and Africa

End-to-End R&D Solutions

From Preclinical Development to Clinical Trials and Commercialization



Preclinical
Development



Clinical
Development



Regulatory &
Integrated Services




Real-World
Evidence



Commercialization
Support



Dedicated to Saving Lives



Founded in 1993, Tofflon is a global pharmaceutical equipment and end-to-end solution provider serving the biopharmaceutical and biotechnology industries. With more than 30 years of experience, Tofflon has delivered 12,000+ equipment and systems to over 3,000 pharmaceutical customers across 50+ countries and regions.

Tofflon has particular expertise in lyophilization, aseptic filling lines, and isolator technologies, providing integrated fill-finish solutions for vials, prefilled syringes (PFS), cartridges, and other injectable products. Our capabilities extend from formulation and compounding through filling, lyophilization, inspection, CCIT, labeling, and secondary packaging, enabling Tofflon to serve as a single-source, end-to-end solution partner from R&D and pilot production to commercial manufacturing.

In North America, Tofflon USA LLC provides dedicated local sales, project coordination, field service, spare parts, and after-sales support, combining Tofflon's global engineering capabilities with responsive local customer service.

WE ARE HIRING | JOIN OUR GROWING TEAM

OPEN POSITIONS



Sales Engineer

Food & Beverage Processing Equipment

Develop new business opportunities and provide technical sales support for customers in the food and beverage processing industry.



Regional Sales Manager

West Coast

Lead and grow sales activities in the West Coast region, develop customer relationships, and drive business growth.



Project Manager

Manage and coordinate projects from planning through execution, ensuring projects are completed on time and meet customer expectations.



Field Service Engineer

Provide installation, commissioning, maintenance, troubleshooting, and technical support for our customers and equipment.

WHY JOIN TOFFLON USA?

- ✓ Growing international company.
- ✓ Career development opportunities.
- ✓ Collaborative and professional work environment.
- ✓ Opportunity to work with advanced processing and pharmaceutical equipment technologies.

Interested in Joining Our Team?

Please submit your resume to
info.us@tofflon.com



Willingjet Life Science Ltd.

Since 2002 · Life Science Translation

Your Global Partner for Regulatory Excellence

WHO WE ARE

Founded in 2002, Willingjet Life Science Ltd. is a trusted Asia-Pacific partner for life-science regulatory and language services. We support pharma, clinical and biotech industries with translation, medical writing, pharmacovigilance reporting, eCTD submissions and registration agency services.

Our multilingual team covers 100+ languages with solid global regulatory knowledge. ISO 9001, 17100 and 27001 certified, we integrate regulatory expertise and innovative technology to empower your global business success.

● Translation ● Medical Writing ● PV Reporting ● eCTD Submissions ● Registration Agency

20+

Years of Excellence

100+

Languages

ISO 9001

17100, 27001
Certified

Contact Us:

Tel: 86+10-80223713

Website: www.willingjet.com

Email address: contact@willingjet.com

Mailing Address: Room 508, F Building, Greenland Central Plaza, Leyuan Road, Daxing District, Beijing 102627, China



WILMINGTON

PHARMATECH

Better API Science.
Reliable American Supply.

Our expertise includes:

- ✓ Complex Synthetic Chemistry
- ✓ Full cGMP Analytical Services
- ✓ cGMP API Manufacturing from development to commercial
- ✓ HPAPI, ADC, & Peptide Manufacturing





WISKIND

Turnkey Cleanroom Solutions



Concept Design



Basic Design



Detailed Design



Material and
Equipment Supply



Aftersales



H.O.



Commissioning & Validation



Construction
Management

Established
in 1978

1978

Over 210 million square meters
of products delivered

210M+

Over 16,000 cleanroom system
projects delivered worldwide

16,000+

Products exported to 70+
countries and regions

70+



CONTACT US

FOLLOW US



[linkedin.com/company/sapa-hq](https://www.linkedin.com/company/sapa-hq)



sapaweb.org



美中药协SAPA



[@SAPA_HQ](https://twitter.com/SAPA_HQ)



[Become Volunteer](#)

CONTACT US



event@sapaweb.org